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Abstract 
Chronic lymphocytic leukemia (CLL) is characterized by accumulation of malignant B cells in blood, 
bone marrow, spleen and lymph nodes. It is the most common leukemia in the Western world. Major 
progress has been made in recent years to prolong the survival and improve the well-being of the patients. 
Despite advances, CLL is still a disease with no cure. New therapeutic strategies, based on new targets 
and novel drugs, are needed. 
Receptor tyrosine kinase-like orphan receptor (ROR1) belongs to one of the twenty families of 
receptor tyrosine kinases (RTKs). RTKs are involved in important cellular processes including 
proliferation, differentiation, survival, signaling and migration. Many RTKs are deregulated in various 
types of cancer and may act as a therapeutic target. ROR1 is highly expressed in CLL and other 
malignancies but not in normal adult cells. ROR1 has been shown to be a survival factor for CLL cells. 
The main goal of the study was to develop novel ROR1 targeting therapeutics for CLL. 
 
In the first study, five monoclonal antibodies (mAbs) directed against different domains of the 
extracellular part of ROR1 were produced and their apoptotic activity was analysed. All five mAbs 
recognized surface bound ROR1 and induced selective apoptosis of CLL cells but not of normal B cells. 
Antibodies alone against CRD and KNG domains of ROR1 were the most effective in inducing apoptosis 
of CLL cells without the need of complement or immune effector cells. KNG and CRD mAbs induced 
higher cytotoxicity than rituximab in vitro. Crosslinking of ROR1 mAbs with F(ab)2 fragments 
significantly enhanced apoptosis. Two of the mAbs also induced complement dependent cytotoxicity 
(CDC) similar to rituximab and one KNG mAb (IgG1) induced antibody-dependent cellular cytotoxicity 
(ADCC). 
In the second study, different ROR1 isoforms as well as the phosphorylation pattern in CLL cells were 
analysed. Two major ROR1 bands with the size of 105 and 130 kDa were identified which may 
correspond to unglycosylated (immature) and glycosylated (mature) ROR1 respectively. The 105 kDa 
band was significantly higher expressed in non-progressive than in progressive CLL patients. Two other 
ROR1 bands with the size of 260 kDa and 64 kDa were also noted which might represent dimerized 
ROR1 and truncated ROR1, respectively. The 64 kDa band was localized to the nucleus indicating a 
possible role as a transcription factor. ROR1 isoforms of 64, 105, 130 and 260 kDa were all 
phosphorylated at tyrosine and serine residues. The phosphorylation intensity for the 130 kDa ROR1 
isoform was significantly higher in progressive than in non-progressive CLL patients. ROR1 mAbs 
against the CRD and KNG domains induced dephosphorylation of ROR1 and subsequent apoptosis of 
CLL cells. 
In the third study, the effect of ROR1 mAbs on PI3K/AKT/mTOR signaling was analyzed. Anti-CRD 
ROR1 mAb induced apoptosis of CLL cells and reduced phosphorylation levels of ROR1 as well as of 
SRC, PI3K, AKT, mTOR, and CREB. An anti-ROR1 mAb against the Ig-like domain did not induce 
apoptosis. 
In the fourth study, the expression of dishevelled (DVL) proteins was investigated. DVL proteins 
(DVL1, DVL2 and DVL3) were significantly upregulated in CLL cells compared to normal PBMC. 
DVL1 and DVL3 expression was higher in progressive than in non-progressive CLL patients whereas 
DVL2 was significantly higher expressed in non-progressive compared to progressive CLL. DVL1, 
DVL2 and DVL3 were phosphorylated at tyrosine and serine residues. The data indicate that DVLs are 
involved in the pathobiology of CLL probably as part of the Wnt signaling pathways. 
In the fifth study, a small molecule that inhibits activated ROR1 (KAN0439834) was described for the 
first time. KAN0439834 induced apoptosis in CLL cells, about 60-fold higher compared to normal 
PBMC. KAN0439834 dephosphorylated ROR1 and seemed to dephosphorylate PI3K, AKT and CREB. 
KAN0439834 showed higher specific killing activity against CLL cells compared to other kinase 
inhibitors. Treatment of NOD-SCID mice xenografted with human CLL cells with KAN0439834 
significantly reduced the number of CLL cells and dephosphorylated ROR1. 
 
In conclusion, mAbs and a first-in-class tyrosine kinase inhibitor against ROR1 showed promising 
results with regard to specific cytotoxicity of CLL cells. Based on these data, ROR1 appears to be a 
suitable target for a novel therapeutic approach of CLL, as well as of other malignancies with a different 
mechanism of action than currently available drugs. 
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1 CHRONIC LYMPHOCYTIC LEUKEMIA 
1.1 Introduction 
Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in the Western 
world which mainly affects individuals with an age more than 50 years and is characterized 
by the progressive accumulation of CD5+ B cells in the peripheral blood, bone marrow and 
lymphoid organs such as lymph nodes and spleen  [1-3]. Previously CLL was considered to 
be a homogenous disease with mature B cells accumulation due to defective apoptosis but 
now several reports have indicated that the high lymphocyte count is due to both prolonged 
survival and high proliferation [4-6]. B cells in CLL express CD5, CD19, CD23 and low 
levels of IgM, IgD and CD79b, which is a phenotype of mature and activated B cells [7-9] as 
depicted in Figure 1. CLL is now considered as a disease of high heterogeneity with regard 
to cell morphology, cytogenetics and immunophenotype and with a varying clinical 
behavior [10]. One-third of CLL patients do not require treatment and survive for more than 
twenty years [11] while some may progress quickly from time of the diagnosis, accompanied 
by complications such as autoimmune phenomena, infections and deterioration. 
 
 
Figure 1. Differential diagnosis of CD19+ lymphocytosis. 
Reprinted from The Lancet, 371(9617):1017-1029, 2008, Dighiero G, Hamblin TJ, “Chronic lymphocytic leukaemia”. 
Copyright (2015), with permission from Elsevier. 
1.2 Epidemiology 
The incidence of CLL varies with age and sex in a given population. CLL is more common 
in men than women with ratio of 1.5-2:1. The number of new CLL cases in Sweden is 
around 500 per year with a median age of 71 years at diagnosis [12]. However, one third of 
new CLL cases are diagnosed under the age of 55 [13]. The prevalence of CLL is around 30-
50/100,000 which is the number of all diagnosed cases at a given moment in time [14]. CLL 
is very rare in Chinese, Japanese and Filipino populations for unknown reasons [15]. The 
incidence rate among them is 5 times lower even if they have fully adopted an American 
lifestyle compared to White Americans [16]. 
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1.3 Risk factors 
There is no evidence that the occurrence of CLL is due to environmental factors such as 
radiations and chemical compounds. No correlation with immunodeficiency problems has 
been reported [2]. The occurrence of CLL is very rare in China and Korea and almost non-
existent in Japan and this extremely low incidence frequency is maintained in Japanese 
emigrants and in their following subsequent generations excluding the environmental 
modifiers of genetic susceptibility [16, 17]. There is also indication that 5-10% of cases might 
be due to familial susceptibility to CLL and other lymphoid malignancies resulting in two 
or more members in the same family with disease [18-20]. The first relatives of CLL patients 
have 2 to 7 times higher risk to develop the disease than the general population [21]. The 
familial predisposition is also related to the earlier onset of a more aggressive course of 
disease in the progeny of CLL patients [20, 22-24]. 
1.4 Biology and pathogenesis 
The development of cytogenetic and molecular biology during the last two decades has 
made a considerable progress in the field of CLL. It is currently suggested that inhibition of 
apoptosis is of major importance for the development of CLL, where B cells show a high 
anti-apoptotic activity with a strong Bcl-2 expression. There exists imbalance between the 
rate of cell birth and death in CLL cells [25, 26]. The accumulation of transformed B cells due 
to defective apoptosis machinery may result in CLL as there exists a very small 
proliferating population of B cells which is one of the hallmark of CLL [27]. 
Monoclonal B cell lymphocytosis (MBL) is the pre-leukemic stage of CLL with 
< 5x109/L of circulating B cells with the absence of lymphadenopathy and disease 
symptoms [28]. Majority of patients go through MBL state for 6 months to 7 years prior to 
development of CLL [29]. Most MBL clones show the same genotype as CLL and recently 
some driver mutations within subclones for development of CLL have been suggested [30]. 
CLL is a dynamic disease with clonal architecture that gets changed over time and is 
also influenced by a selection process. The first oncogenic transformation from MBL to 
CLL is not known but the presence of oligoclonal B cell clones in MBL and CLL indicate 
the probability of generating B cell clones may have been acquired as back as self renewing 
hematopoietic stem (HSC) cell with germ line IGH genes [31]. Next generation sequencing 
(NGS) has made it possible to detect mutations in smaller subclones. The presence of 
mutations in subclones may lead to heterogeneity and different response to therapies in 
CLL [32, 33]. However, more studies are needed to understand the exact mechanism of 
formation of mutated subclones. 
The BCR (B-cell receptor) is present on the surfaces of both normal and malignant B 
cells and composed of antigen-specific surface membrane immunoglobulin M (sIgM) and 
the CD79a and CD79b heterodimers. Somatically mutated immunoglobulin (Ig) variable 
genes are present in CLL cells. The number of somatic hypermutations (SHM) in the heavy 
chain variable region of immunoglobulin genes (IGHV) may determine two CLL 
subgroups as mutated and unmutated CLL. In unmutated CLL, there is 98% or more 
sequence similarity of the IGHV gene with corresponding germline sequence while less 
than 98% for mutated CLL [34, 35]. About half of the CLL patients belong to each group with 
different prognosis associated with IGHV mutational status [34-36]. 
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CLL cells may originate from antigen-experienced B cells as there are similarities 
between normal memory B cell and the CLL cell as well as mutated and unmutated CLL 
cells [37]. This observation may suggest the involvement of antigen-driven process in the 
pathogenesis of CLL. The presence or absence of somatic mutations in the stereotyped 
receptors may suggest the contribution of common set of antigens to CLL pathogenesis [38-
40]. The stereotyped receptors are more common in unmutated than mutated CLL patients 
and is associated to affect prognosis as demonstrated for IGHV3-21 subgroup [38, 39, 41]. 
Many exogenous as well as autoantigens have been suggested to be involved in the 
malignant transformation process. 
The BCR signaling in CLL may be induced independent of antigens. About 50% of 
CLL patients have self-recognizing epitopes that result in the autonomous and constitutive 
activation of BCRs [42]. Basal signaling has been shown to be higher in CLL cells as 
compared to normal B cells and it was particularly elevated in IGHV mutated CLL cells [43]. 
The absence of activating mutations in BCR genes in CLL may suggest the involvement of 
both autonomous and external antigen in the stimulation of receptors [44]. 
1.5 Diagnosis of CLL 
The diagnosis of CLL is carried out by blood count, analyzing blood smears and immune 
phenotype from blood samples. The presence of 5x109/L or more B-lymphocytes in the 
peripheral blood is the prerequisite of CLL [45]. CLL cells are characterized by weak sIg 
levels and express CD5, B-cell antigen CD19, CD20 and CD23. The levels of CD20 and 
CD79b in CLL cells are very low as compared to normal B cells. A bone marrow aspirate 
is recommended in cases with cytopenia to differentiate between bone marrow infiltration 
or autoimmune cause. Analysis of bone marrow is also recommended before treatment 
initiation [45]. 
Most patients have no symptoms at the time of diagnosis. The most common 
symptoms are night sweat, fatigue, weight loss, lymph node swelling, hepatosplenomegaly 
and other symptoms due to bone marrow failure. Patients with CLL may be accompanied 
by autoimmune complications and recurrent infections [1, 45-47]. 
1.5.1 Staging systems 
CLL is categorized into different prognostic groups by a system based on clinical staging 
introduced by Rai et al  [46, 48] and Binet et al [47]. Clinical stages of CLL are defined by the 
presence of anemia/thrombocytopenia, number of regions with enlarged lymph nodes, 
hepatomegaly and splenomegaly. The platelet count to define Binet stage C and Rai stage 
IV is the same at 100,000 platelets/μl [45] but defining anemia based on hemoglobin level is 
different for the two systems with cut-off of 100 g/L for a Binet stage C and 110 g/L for 
Rai stage III. 
Both staging systems estimate the prognosis of patient; the median survival for Binet 
stage A or Rai stage 0 (low risk) is more than 10 years, 5-7 years for Binet stage B or Rai 
stage I-II (intermediate risk) and 2-3.5 years for Binet stage C or Rai stage III-IV (high 
risk), the patients in high risk group are accompanied by anemia and thrombocytopenia [46-
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48]. A limitation of the Rai and Binet staging systems is that they are unable to predict 
disease progression at an early stage (Binet A or Rai 0). 
1.5.2 Morphology of CLL cells 
The staging systems are based on the morphology of CLL cells in the blood and bone 
marrow, mostly of mature appearance. Atypical morphology of CLL cells in a blood smear 
and a high number of pro-lymphocytes or diffuse infiltration in the bone marrow are linked 
to a poor prognosis [46, 47, 49, 50]. On the other hand, high number of smudge cells may 
indicate a good prognosis [51]. 
1.5.3 Lymphocyte doubling time 
Lymphocyte doubling time (LDT) is the time period during which the absolute 
lymphocytes count gets double indicating the activity of the disease. LDT longer than 12 
months is related to increased progression free and overall survival [52, 53]. On the other hand 
LDT of less than six months indicates active disease and should be recommended for 
treatment but only when lymphocyte count is above 30,000 lymphocytes/μl [45]. The 
shortcoming of using LTD is that once high lymphocytes counts have been reached and 
some patients with stable absolute lymphocyte counts have still high CLL cell birth rates 
than 1% of the entire leukemia clone per day [5]. However, using LTD for disease 
assessment is simple and reliable. 
1.5.4 Serum markers 
There are three serum markers which act as important prognostic factors for CLL patients; 
serum β2-microglobulin (sβ2m), soluble CD23 (sCD23) and serum thymidine kinase 
(sTK). The advantage of serum markers is the simple way of blood sampling and reliability 
of assessments, but still they are not widely applied in Europe for CLL patient 
management. 
High level of sβ2m in CLL patients relates to poor prognosis such as advanced disease 
stage, bone marrow infiltration and high tumor burden [54, 55]. The sβ2m levels are also 
correlated with the expression of other adverse prognostic factors as CD38 and zeta-
associated protein (ZAP70) [56].  
The cellular enzyme sTK is usually found in dividing cells and absent in non-dividing 
cells which serves as a useful marker for proliferation and is associated with disease 
progression and advanced stage [57, 58]. Elevated level of sTK has been shown to correlate 
with other prognostic factors such as LDT, ZAP70, cytogenetic abnormalities and CD38 in 
Binet stage A patients [59]. 
High levels of sCD23 correlated with tumor mass, short LDT, diffuse bone marrow 
infiltration, early stage disease progression and reduced survival [60, 61]. 
1.5.5 Cytogenetic abnormalities 
Some of the genomic aberrations as prognostic markers used in CLL are shown in Figure 2. 
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The most common cytogenetic abnormalities which can be used as prognostic factors are 
deletions of the long arm of chromosome 13 (del (13q)), long arm of chromosome 11 (del 
(11q)) and short arm of chromosome 17 (del (17p)) as well as trisomy 12q. These 
cytogenetic abnormalities can be assessed by interphase fluorescence in situ hybridization 
(FISH). Patients with del (17p) have the worst prognosis (median overall survival of 32 
months), followed by del (11q) (79 months), trisomy 12q (114 months) and normal diploid 
karyotype (111 months) whereas patients with del (13q) have the best prognosis with a 
median overall survival of 133 months [62]. Patients with del (11q) and del (17p) are also 
related to other adverse prognostic factors such as IGHV mutational status, advanced stage 
and rapid disease progression, poor response to treatment and a short survival [63, 64]. The 
cytogenetic abnormalities have an important role for treatment decisions.  
A TP53 mutation in CLL is related to short time to treatment and short overall survival 
(OS) regardless of 17p deletion [65-67]. TP53 mutations in CLL patients with mutated IGHV 
have demonstrated better survival than those with unmutated IGHV gene. TP53 mutations 
and 17p deletion have been associated with poor response to chemotherapy [65, 68] and are 
thus clinically important markers that should be assessed before every new line of 
treatment [45]. 
 
Figure 2. Probability of survival 
from the date of diagnosis among 
patients in the five genetic 
categories.  
The median survival times for the 
groups with 17p deletion, 11q 
deletion, 12q trisomy, normal 
karyotype, and 13q deletion as the sole 
abnormality were 32, 79, 114, 111, 
and 133 months, respectively.  
Reproduced with permission from  
N Engl J Med 2000; 343:1910-1916,  
Döhner H, Genomic Aberrations and  
Survival in Chronic Lymphocytic Leukemia. 
Copyright Massachusetts Medical Society. 
1.5.6 IGHV mutation status 
During development of normal B-lymphocytes, a number of changes take place in 
immunoglobulin genes including mutation of IGHV genes. CLL patients with somatic 
mutations in IGHV genes are usually associated with del (13q) and Binet stage A and have 
good prognosis  [63, 64]. On the other hand, patients with un-mutated IGHV are more likely 
to be in advanced disease stage, to have an aggressive course and more prone to get 
cytogenetic aberrations [69, 70]. CLL patients with un-mutated IGHV genes have overall 
survival of approximately 8 years while patients with mutated IGHV gene have around 25 
years. The IGHV mutational status for patients has been shown to be closely correlated to 
17p deletion 
11q deletion 
12q trisomy 
Normal 
13q deletion as sole  
abnormality 
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the expression of ZAP70 and CD38 [35, 71]. The mutational status of CLL patients (whether 
mutated or unmutated) remains unchanged during disease evolution. 
1.5.7 ZAP-70 
ZAP-70 (Zeta-chain-associated protein kinase 70), a member of Syk-ZAP-70 protein 
tyrosine kinase family, normally expressed in T and NK cells and plays key role in 
initiation of T-cell signaling. ZAP70 protein is also expressed on CLL cells but not on 
normal B cells and its expression remains constant over the course of disease. The 
expression of ZAP70 may be used in predicting the treatment free survival and overall 
survival outcomes. The expression of ZAP70 is considered superior compared to 
expression of CD38 or IGHV mutation status in predicting time to first treatment even in 
patients with early stage asymptomatic disease [72]. The concordance between ZAP70 and 
IGHV mutational status lies in the range of 77-95%. A 5.5-fold higher ZAP70 expression 
was noted in those with un-mutated IGHV status compared to those with mutated IGHV 
[73]. However the expression of ZAP70 might not provide any further prognostic 
information when used in addition to CD38 and IGHV mutational status and is thus seldom 
used in routine health care. 
1.5.8 CD38 
CD38 is a transmembrane protein receptor that can function in cell adhesion, signal 
transduction and may act as an enzyme. Patients with elevated level of CD38 expression on 
the CLL cells are associated with adverse prognosis including advanced stage, 
hepatomegaly, elevated sβ2m, high-risk cytogenetics, short LDT, poor response to therapy 
and short overall survival [49]. CLL cells with un-mutated IGHV genes express high levels 
of CD38 but the association between CD38 expression and IGHV mutational status is not 
absolute. CD38 expression may vary during the course of the disease [49]. CD38 is thus an 
important prognostic factor but is not a perfect surrogate marker for IGHV mutation status 
and not recommended by Swedish CLL guidelines. 
1.5.9 Other prognostic markers 
There are a few other molecular markers that have recently been suggested as prognostic 
markers. Among them are NOTCH1, SF3B1, BIRC3, MYD88, lipoprotein lipase (LPL) 
and CLL up-regulated gene 1 (CLLU1) as well as miRNA. 
Mutated NOTCH1 is associated with a shorter time to treatment and survival as well as 
resistance to chemotherapy [74-77]. However, mutated NOTCH1 was shown to be not an 
independent prognostic marker for time to treatment, PFS or OS [66, 68]. 
Patients with mutated MYD88 and 13q deletion may have better OS compared to wild-
type patients [74, 78]. Mutated SF3B1 is also related to poor prognosis and advanced stage 
disease [68, 79, 80]. However, a recent study showed that mutated SF3B1 was only an 
independent marker for shorter PFS but not OS [68]. After TP53 mutation and IGHV 
mutational status, SF3B1 seems to be a strong prognostic marker in patients receiving first 
line treatment [68]. 
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Mutated BIRC3 has been associated with short OS and resistance to chemotherapy [81]. 
Mutations in BIRC3 have been also linked to fludarabine refractoriness and are observed in 
40% of fludarabine resistant CLL with TP53 wild type [78, 81].  
The expression of LPL has been associated with poor prognosis and might be useful in 
evaluation of low risk patients [82]. 
Overexpression of CLLU1 has been associated with poor prognosis and advanced 
stage disease and shorter time to treatment but it is neither a predictive nor an independent 
prognostic marker [82]. CLLU1 may be a useful prognostic marker to identify younger 
patients who need treatment. miRNA expression has been shown to be different between 
prognostic subgroups and therefore may be used as prognostic markers [82]. 
Further studies are needed to identify novel markers that could predict the response to 
therapy. 
1.6 Microenvironment 
The tumor microenvironment in the lymph nodes and bone marrow is essential for survival 
of CLL cells. The CLL microenvironment is illustrated in Figure 3. Microenvironment 
provides a niche for CLL cells to interact and cross talk with cytokines, chemokine and 
other accessory cells. CLL cells isolated from patients undergo spontaneous apoptosis that 
could be prevented by culturing with cytokines, bone marrow stromal cells and accessory 
cells [83]. This implies that CLL cells need a favorable environment and an external stimulus 
for their proliferation and survival. 
Proliferation of CLL cells occurs predominantly in lymph nodes [84]. Proliferation 
centers (PC) also known as pseudofollicles are the tissues sites in lymph nodes and bone 
marrow where proliferation takes place. PC presents an environment where CLL cells 
interact with antigens and accessory cells (mesenchymal stromal cells (MSC), monocyte 
derived nurse-like cells (NLC) as well T cells) [44, 85]. 
Adhesion molecules mediate migration of CLL cells to secondary lymphoid organs. 
Integrins are heterodimeric glycoproteins that mediate cell-cell and cell-matrix adhesion. 
High levels of integrin CD49d and CD38 in CLL are associated with potential for higher 
migration towards CXCL12 chemokine [44]. CLL cells from secondary lymphoid organs are 
then guided by chemokines into the tissues by a phenomenon known as homing [85]. Highly 
expressed chemokine receptor CXCR4 on CLL cells is attracted by a chemokine CXCL12 
resulting in chemotaxis and migration [86]. The chemokine CXCL12 is secreted by MSC. 
Stimulated CXCR4 activates PI3K and MAPK pathways resulting survival effects for CLL 
cells [87]. PI3K, BTK and SYK inhibitors can inhibit the survival and stimulatory effects 
induced by CXCR4 in CLL cells [88-90]. Stimulated CLL cells secrete CCL3/4 chemokines, 
which attract monocytes and T cells [91]. High level of CCL3/4 in plasma has been 
associated with poor outcome in CLL [92]. BMSCs also appear to activate lymphoid-proto 
oncogene TCL1 (T-cell leukemia/lymphoma protein 1) and subsequent activation of NFκB 
and protein kinase C (PKC) [85]. 
NLCs can be found in spleen and lymphoid tissues but their mechanism of 
differentiation from blood monocytes is not clear. In vitro, CLL cells stimulate NLC 
differentiation by activating TLR-9 (toll-like receptor 9) [44]. NLCs attract CLL cells by 
secreting CXCL12 and CXCL13 and guide them to be in close contact with CXCR4 and 
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CXCR5. CXCL12 acts as co-stimulatory factor for CD4+ T cells in CLL cells [93]. NLCs 
also activate BCR signaling and NFκB pathways. NLC also expresses CD31, which by 
binding to CD38 on CLL cells stimulates survival [44]. CD4+ T cells secrete CD40L and IL-
4 which are important for proliferation and survival of B cells via NFκB [44]. CD40L 
binding to CD40 may also activate PI3K pathway, which is important for survival and 
proliferation of CLL cells. 
NFκB pathway can be activated by several ways including the stimulation of TLR and 
CD40 as well as BCR signaling. BMSC, NLC, cytokines, chemokines and activated CD4+ 
T cells provide a very favorable niche for survival of CLL cells and also protect them 
against immune-chemotherapy ensuing resistance to drugs [85, 93, 94]. Disruption of the 
interactions and cross talks in microenvironment may present a very good therapeutic 
option for the treatment of CLL. 
 
Figure 3. The CLL microenvironment. 
 
A) In the CLL microenvironment, CLL cells interact 
with bone marrow stromal cells (BMSC) and nurse 
like cells (NLC) through adhesion molecules and 
chemokine receptors, expressed on CLL cells. These 
interactions, in addition to B-cell receptor 
engagement, promote CLL survival, proliferation, 
and homing to tissues. 
 
B) CD4+ T cells are recruited into the tissue 
microenvironment by CLL cell–derived chemokines, 
including CCL3 and CCL4, to support CLL cell survival 
and proliferation. Inhibitory receptors expressed by CLL 
cells induce defective immune synapse formation 
between CLL and T cells. Cytotoxic granule secretion 
by CD8+ T cells is also defective, and production of 
soluble factors by CLL cells suppresses NK cell 
cytotoxicity, favoring immune evasion of CLL cells. 
Reprinted from Clin Cancer Res 2014;20:548-556, ten Hacken E, Burger JA, Molecular Pathways: Targeting the Microenvironment 
in Chronic Lymphocytic Leukemia - Focus on the B-Cell Receptor, with permission from AACR. 
1.7 Treatment 
CLL is still an incurable disease but various treatment approaches are used to control 
symptoms and prolong survival of patients. With the application of Rai and Binet staging 
system advantages of various interventions can be acknowledged [46]. During last two 
decades, the discovery of increasing number of prognostic markers has led to a better 
understanding of the heterogeneity of the disease. Risk stratification is helpful in deciding a 
particular treatment approach [95]. Depending upon the clinical situation, different options of 
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treatments are considered, which may include the use of conventional agents or other 
recently developed combination approaches [96-99]. Recently, a number of new agents have 
shown promising clinical activity and some have been approved for the treatment of CLL. 
The increasing number of new agents offers the future potential to achieve long-term 
control and stabilization of the disease. 
1.7.1 Cytotoxic agents 
1.7.1.1 Alkylating agents 
Alkylating agents, the initial therapy for CLL, were successful to control clinical 
manifestations and reduce CLL cell number in blood. Chlorambucil was the gold standard 
for CLL therapy for a long time and even today is an appropriate but moderately effective 
option for elderly CLL patients with co-morbidities. The advantages of chlorambucil are 
low cost, moderate side effects and its convenient oral use. However, this treatment has 
relatively low response rates when used as monotherapy (ORR up 30-70% and CR only 0-
7%) and a median progression free survival (PFS) of 8-18 months [96, 100, 101]. With 
combination as alkylating agent based chemotherapy, significant numbers of complete 
responders were observed in various clinical trials but the disease was never cured as the 
patients eventually relapsed at some point [102-105]. Phase II studies of chlorambucil in 
combination with rituximab in elderly patients showed better ORR (84% and 82.4%), CR 
rates (10% and 16.5%) and PFS (23.5 and 34.7 months) than previously achieved with 
chlorambucil as monotherapy [100, 106]. The combination was well tolerated with comparable 
toxicities to chlorambucil alone. A phase III study combining obinutuzumab, a CD20 mAb, 
with chlorambucil in untreated CLL patients showed significantly better response with CR 
rates (20.7% vs. 7.0%), more minimal residual disease (MRD) negative (19.5% vs. 2.6%) 
and PFS (median PFS 27.6 vs. 16.3) compared to those treated with rituximab-
chlorambucil combination [107]. Chlorambucil in combination with ofatumumab showed 
better clinical activity with manageable side effects in CLL patients who were not suitable 
for fludarabine treatment  [108]. 
1.7.1.2 Purine analogs 
Purine analogs are cytotoxic agents with established activity in indolent lymphoid 
malignancies. Deoxycoformycin also known as pentostatin was the first purine analog to 
enter clinical trials with promising results [109]. Pentostatin in combination with an 
alkylating agent (cyclophosphamide) and a CD-20 monoclonal antibody (PCR) is effective 
but not widely used in health care front-line therapy [110, 111]. The other two used purine 
analogs in CLL are fludarabine and cladribine. Fludarabine is the most studied purine 
analog in CLL. Fludarabine induced more remission and more complete remissions (CR) 
(7%-40%) than other conventional chemotherapies but as a single agent it did not improve 
overall survival (OS) [112-115]. Fludarabine in combination with cyclophosphamide [116] 
served as the basis and later combined with rituximab (FCR), which is now considered as 
the golden standard frontline therapy in CLL [116, 117]. FCR has shown ORR of about 90% 
and CR rates of 44% and has prolonged PFS of 57.9 months as well as improved OS versus 
FC alone  [118, 119]. Even though FCR has shown better response rates and improved survival 
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but it is less well tolerated in patients older than 70 years of age [120, 121]. Therefore FCR is 
not a first line treatment for all patients as it is too toxic for elderly and fragile patients who 
constitute a large fraction of all CLL cases. Similarly, cladribine another purine analog 
showed promising results with complete and partial remissions of 38% and 37% 
respectively in untreated patients but did not prolong overall survival when used as 
monotherapy [122, 123]. It is today mainly used in hairy cell leukemia. Bendamustine was 
used in randomized trial resulting improved response but more with toxicity and no overall 
survival [96]. Bendamustine in combination with rituximab (BR) is an option for patients 
with borderline fitness status. BR has demonstrated response rates (ORR 88%, CR 23.1%) 
but with less neutropenia (19.7% vs. 34%) but severe infections (7.7% vs. 25%) when 
compared to FCR [124]. 
Even with more aggressive approach such as FCR, the eradication of the disease at the 
molecular stage is still not possible and side effects like immunosuppression with resultant 
infections and possibly increased risk of secondary malignancies have been reported [125, 
126]. 
1.7.2 Allogeneic stem cell transplantation 
Allogeneic stem cell transplantation has been employed for around three decades for the 
treatment of CLL and updates confirm its efficiency in the long-term control or even 
eradication of disease [127]. Recently, panel of experts has indicated that allogeneic stem cell 
transplantation is a reasonable treatment option for younger patients, non responsive to 
standard therapies and patients with p53 abnormalities who need treatment. However, its 
role has been questioned in patients who continue to respond to the new BTK inhibitor 
ibrutinib. 
1.7.3 Monoclonal antibody therapies 
The most specific treatment approach is to target structures and molecules that are limited 
only to malignant cells. The presence of immunoglobulin on B cells in non-Hodgkin 
lymphoma showed the practicability of this approach [128]. In this approach, using unique 
idiotypes convinced scientists to focus on producing antibodies utilizing less specific but 
more generalized tumor antigens as targets. Mainly unconjugated antibodies have been in 
use and the mechanisms of tumor cells cytotoxicity are complement dependent cytotoxicity 
(CDC), antibody-dependent cell cytotoxicity (ADCC) and signaling apoptotic pathways. In 
CLL, antibodies against target antigens CD20 and CD52 are used [129, 130]. In Table 1, a 
number of therapeutic monoclonal antibodies for various malignancies have been 
summarized [131]. 
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Table 1. Therapeutic monoclonal antibodies targeting non-tyrosine kinase molecules. 
Name Trade name Target Antibody format Targeted cancer (examples) 
Alemtuzumab Campath CD52 Humanized IgG1 CLL, CTCL, TCL 
Brentuximab vedotin  
(ADC) 
Adcetris CD30 Chimeric IgG1 Systemic anaplastic large 
cell lymphoma, Hodgkin's 
lymphoma  
Catumaxomab Removab CD3 and EpCAM Mouse biospecific  
mAb against  
Malignant ascites generated 
by an EpCAM-positive 
tumor malignant lung cancer
Dacetuzumab - CD40 Humanized IgG1 NHL 
Denosumab Prolia RANKL Humanized IgG2 Non-metastatic prostate 
cancer 
Gemtuzumab ozogamicin Mylotarg CD33 Humanized IgG4 AML 
Ibritumomab tiuxetan 
(ADC) 
Zevalin  CD20 Mouse IgG1 B-cell NHL 
Ipilimumab 
(MDX-010/ MDX-101) 
Yervoy CTLA-4 Humanized IgG1 Metastatic melanoma 
Labetuzumab CEA-CIDE CEA Humanized IgG1 Colorectal carcinoma 
Lumiliximab - CD23 Humanized IgG1 CLL 
Milatuzumab - CD74 Humanized IgG1 Multiple myeloma, NHL, 
CLL 
Obinutuzumab Gazyva CD20 Humanized IgG1 CLL 
Ofatumumab 
(HuMax-CD20) 
Arzerra CD20 Humanized IgG1 CLL 
Pembrolizumab Keytruda PD-1 Humanized IgG4 Metastatic melanoma 
Rituximab Rituxan 
(MabThera) 
CD20 Humanized IgG1 B-cell NHL, CLL 
Tositumomab Bexxar  CD20 Mouse IgG2 B-cell NHL, FL 
Veltuzumab - CD20 Humanized IgG1 B-cell NHL, CLL 
Vivatuxin - Intracellular DNA-
associated antigens 
Radiolabeled chimeric 
IgG1κ 
Malignant lung cancer 
90Y-Ibritumomab 
tiuxetan/ 
Zevalin CD20 90Y labelled Anti-, 
deliver Y-90, murine 
IgG1 
Follicular B-cell NHL 
CLL: chronic lymphocytic leukemia, CTCL: cutaneous T-cell lymphoma, TCL: T-cell lymphoma, ADC: antibody-drug conjugate, 
EpCAM: epithelial cell adhesion molecule, NHL: non-Hodgkin’s lymphoma, AML: Acute myeloid leukemia, CTLA-4: cytotoxic  
T-lymphocyte antigen-4, CLL: chronic lymphocytic leukemia, PD-1: programmed cell death 1 receptor, FL: follicular lymphoma. 
 
1.7.3.1 Rituximab 
Rituximab is directed against CD20 epitope, was the first monoclonal antibody approved 
for the treatment of lymphoproliferative disorders. It showed modest results in CLL after 
completions of phase I studies as compared to its use in non-Hodgkin lymphoma as single 
agent therapy [132]. Low expression of CD20 was perceived to be the primary reason for its 
weak activity as single agent [133]. Modulation of CD20 by bortezomib, epigenetic alteration 
of gene expression and use of higher doses may improve rituximab efficacy [134-136]. 
However, as mentioned above, rituximab (R) in combination with fludarabine and 
cyclophosphamide (FC) has become the standard front-line treatment in CLL after studies 
showing significant activity [118]. Rituximab has proved to be effective in treating 
complications of CLL including autoimmune hemolytic anemia (AIHA) and pure red cell 
aplasia (PRCA) [137-139]. New novel antibodies against CD20 challenging rituximab are now 
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being explored [140-142]. Rituximab maintenance after chemoimmunotherapy induction in 
CLL showed feasibility [143].  
1.7.3.2 Ofatumumab 
Ofatumumab is fully humanized antibody recognizing an epitope different than the one 
recognized by rituximab on CD20 molecules expressed on human B cells. Ofatumumab 
has stronger binding affinity to CD20 and results in more cytotoxicity due to greater 
complement-dependent cytotoxicity and similar antibody-dependent cellular cytotoxicity 
activity compared to rituximab, specially in cells with low CD20 expression [144]. 
Ofatumumab has shown activity in patients who are refractory to fludarabine and 
alemtuzumab [145, 146]. Ofatumumab in combination with fludarabine and cyclophosphamide 
shows significant activity in the initial treatment of patients with high risk [147] but has not 
become standard therapy. However, ofatumumab in combination with bendamustine was 
recently approved by EMA based on promising phase II results [148]. However, the overall 
activity of ofatumumab in patients with 17p deletion and bulky disease has been shown to 
be modest. Recent data indicate a potential role for ofatumumab as a maintenance therapy 
for relapsed CLL with no unexpected toxicities [149]. A recent retrospective follow up of 
ofatumumab in relapsed/refractory CLL patients treated in a community-based setting 
showed an ORR of only 23% and OS of 12 months [150]. A phase III study of ofatumumab 
in combination with chlorambucil demonstrated improved clinical results in patients with 
CLL who had not received prior therapy and who were considered inappropriate for 
fludarabine based therapy [108]. 
1.7.3.3 Alemtuzumab 
Alemtuzumab is fully humanized monoclonal antibody directed against CD52 antigens 
expressed on lymphocytes as well as monocytes, granulocytes, eosinophil and 
macrophages. Alemtuzumab, as single agent treatment has produced response rates of 33% 
to 53% with duration of response ranging from 8.7 to 15.4 months in advanced stage CLL, 
who were previously treated with alkylating agent and had not responded or relapsed after 
second line fludarabine treatment [130, 151, 152]. Its mechanisms of cytotoxicity are ADCC, 
CDC and direct cell death and works independently of p53 abnormality seen in resistant 
CLL [153]. Alemtuzumab has shown effective responses in high-risk patients with deletion 
of 17p, 11q and p53 mutation [153, 154]. Therefore, alemtuzumab has been a reasonable 
single-agent treatment option for patients with poor prognostic (17p-) features. The 
antibody is today available for CLL patients at no cost through a named patient program 
after having been re-launched under a new name (LemtradaTM) for multiple sclerosis. 
1.7.3.4 Other monoclonal antibodies and immunoconjugates 
Obinutuzumab (GA101) is humanized and glycoengineered monoclonal antibody against 
CD20 which differs in its binding properties from rituximab and ofatumumab. It showed 
higher rates of apoptosis in malignant B cells in vitro as compared to rituximab [155]. The 
humanization and glycoengineering lead to higher affinity binding to CD20 type II epitope, 
increased ADCC, low CDC and increased direct cell death induction [156]. A phase I study 
with obinutuzumab in 13 CLL patients showed promising results with reported side effects 
including neutropenia, thrombocytopenia and tumor lysis syndrome [156]. Combination of 
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obinutuzumab with chlorambucil as compared to chlorambucil alone prolonged overall 
survival [107]. Obinutuzumab+chlorambucil as compared to rituximab+chlorambucil 
resulted in prolonged PFS and higher rates of CR (20.7% vs. 7.0%), though infusion related 
reactions and neutropenia were more common in obinutuzumab+chlorambucil but the risk 
of infection was not increased. 
Other monoclonal antibodies that have shown some activity include HU1D10, 
humanized antibody against a variant epitope on HLA-DR B chain [157]. HU1D10 has 
demonstrated activity in clinical studies of CLL [158]. Examples of other monoclonal 
antibodies with potential activity include lumiliximab directed against CD23 induced 
ADCC and apoptosis in CLL cells [159], TRU-016 (otlertuzumab) directed against CD37 
with phase I clinical trials [160], XmAb5574 against CD19 and epratuzumab against CD 22 
[161].  
Attempts are made to augment the therapeutic efficacy of monoclonal antibodies by 
conjugation (immunoconjugates) with other reagent like toxins. LMB-2, a conjugate using 
a pseudomonas exotoxin, directed against CD25 [162] and BL-22 against CD-22 have 
demonstrated significant responses in CLL [163]. Other antibodies under investigation are 
milatuzumab (CD74), cirmtuzumab (ROR1) and samalizumab (CD200). 
1.7.4 BCR signaling and other kinase inhibitors 
Many small therapeutic molecules are being explored currently in various types of cancer, 
and some of them are described below (Table 2) [131]. 
14 Chronic lymphocytic leukemia 
 
Table 2. Current inhibitors approved for cancer treatment. 
Name Trade name Mol. mass (g/mol) Target molecule/s 
FDA approved or in phase III 
clinical trial for treatment 
Anastrozole Arimidex 293.366 Aromatase inhibitor Breast cancer 
Alitretinoin Panretin 300.435 Retinoic acid 
receptors retinoid X 
receptors 
Cutaneous lesions in patients with 
AIDS-related kaposi sarcoma 
Aflibercept Zaltrap 96900 VEGF Metastatic colorectal cancer 
Belinostat ND 318.348 HDACs T-cell lymphomas 
Bexarotene Targretin 348.478 Retinoic acid 
receptors 
CTCL 
Bortezomib Velcade 384.237 Proteasome 
inhibitors 
Multiple myeloma, MCL 
Carfilzomib Kyprolis 719.91 Proteasome 
inhibitors 
Multiple myeloma 
Deforolimus ND 990.2 mTOR Advanced soft tissue, bone sarcoma 
Denileukin diftitox Ontak 57647.3 IL-2 receptors CTCL 
Entinostat ND 376.4 HDACs Breast cancer, Hodgkin's 
lymphoma, lung cancer 
Everolimus Afinitor 958.224 mTOR Advanced kidney cancer, 
subependymal giant cell 
astrocytoma, MBC, pancreatic 
neuroendocrine tumors, advanced 
renal cell carcinoma 
Exemestane Aromasin 296.403 Aromatase inhibitor Breast cancer 
Ibrutinib Imbruvica 440.49 Btk (IMiD agent) CLL, MCL, DLBCL 
Idelalisib Zydelig 415.42 PI3K (P110δ) CLL, Follicular lymphoma, SLL 
Iniparib ND 292.03 PARP Glioblastoma 
Lasofoxifene Fablyn 563.64 ER ER-positive breast cancer 
Lenalidomide Revlimid 259.261 IMiD agent Multiple myeloma, CLL, MCL 
Letrozole Femara 285.303 Aromatase inhibitor Breast cancer 
Mocetinostat ND 396.44 HDACs Follicular lymphoma, Hodgkin's 
lymphoma, AML 
Olaparib AZD-2281 435.08 PARP Ovarian, breast, prostate cancers 
Pladienolide ND 536.7 spliceosome Gastric cancer, 
panobinostat ND 349.426 HDACs Hodgkin's Lymphoma, CTCL 
Pralatrexate  Folotyn 477.47 Antifolate TCL 
Raloxifene Evista 473.584 ER ER-positive breast cancer 
Romidepsin Istodax 540.695 HDACs CTCL 
Rucaparib ND 323.36 PARP Ovarian, breast, prostate cancers 
Sirolimus Rapamune 914.172 mTOR Hepatocellular carcinoma 
Tamoxifen Nolvadex/Istubal/ 
Valodex 
563.638 ER ER-positive breast cancer 
Temsirolimus Torisel 1030.28 mTOR Renal cell carcinoma 
Toremifene Fareston 405.959 ER ER-positive breast cancer, prostate 
cancer 
Tretinoin Vesanoid 300.4412 Retinoic acid 
receptors 
Acute promyelocytic leukemia 
Veliparib ND 244.29 PARP Melanoma, breast cancer, NSCLC 
Vorinostat Zolinza 264.32 HDACs CTCL 
AIDS: Acquired immunodeficiency syndrome, VEGFR: vascular endothelial growth factor receptor, HDAC: histone deacetylase, CTCL: 
cutaneous T-cell lymphoma, MCL: mantle cell lymphoma, mTOR: mammalian target of rapamycin, DLBCL: diffused large B-cell 
lymphoma, ND: not determined, AML: Acute myeloid leukemia, TCL: T-cell lymphoma, ER: estrogen receptor, PARP: poly ADP ribose 
polymerase, NSCLC; non-small cell lung carcinoma, SLL; small lymphocytic leukemia. 
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1.7.4.1 Idelalisib (CAL-101) 
PI3K pathway regulates cellular functions related to oncogenesis. PI3K p110δ isoform 
plays an important role in the proliferation and survival of B cells [164]. In CLL, a PI3K 
pathway has been shown to be constitutively activated and dependent on PI3K p110δ 
isoform [88]. Idelalisib has been approved by FDA and EMA for the treatment of relapsed 
CLL and follicular lymphoma (FL). Idelalisib is a reversible selective inhibitor of PI3Kδ 
isoform that promotes apoptosis in primary CLL cells in time and dose-dependent manner 
without affecting normal T cells or natural killer (NK) cells [165]. Idelalisib induces caspase-
dependent apoptosis, inhibits BCR survival signals and protective effect of stromal cells 
and with down-regulation of chemokine and cytokine secretion. In a phase I clinical trial, 
idelalisib showed reasonable toxicity with favorable clinical activity (lymph node 
regression) in heavily pretreated and high risk CLL patients [166]. 81% of the patients 
showed lymph node response. Side effects like fatigue, diarrhea, rash and respiratory tract 
infections were observed. In relapsed patients, idelalisib monotherapy achieved an ORR of 
54% and PFS of 5 months in those with TP53 mutations to 72% and 41 months those 
without TP53 mutation [167]. In a phase 3 study, the efficacy and safety of idelalisib in 
combination with rituximab in relapsed CLL patients were assessed [168]. The combination 
of idelalisib and rituximab as compared to rituximab and placebo significantly improved 
progression-free survival, response rates and overall survival in relapsed patients who were 
not appropriate to undergo chemotherapy. Preclinical data suggests that idelalisib may be a 
treatment choice for patients with progressive disease undergoing ibrutinib treatment [169]. 
IPI-145 (duvelisib) is another orally available PI3K inhibitor against both δ and γ 
isoforms. IPI-145 showed activity in CLL patients with advanced stage disease in phase I 
study with reasonable toxicity. The ORR was similar for patients with and without TP53 
mutations. Phase III study of IPI-145 in relapsed CLL patients is currently ongoing. 
1.7.4.2 Ibrutinib (PCI-32765) 
Bruton’s tyrosine kinase (BTK) is involved in the activation of downstream survival 
signaling pathways such as NF-κB and MAPKs through Src family kinases. Ibrutinib is an 
orally active small molecule inhibiting BTK irreversibly that plays an important role in the 
transduction of BCR signaling [170]. This inhibitor has also been shown to inhibit the 
microenvironmental stimuli [171]. FDA approved Ibrutinib in the US for the treatment of 
mantle cell lymphoma (MCL) in November 2013 and for CLL in January 2014. Inhibition 
of BTK with ibrutinib induced apoptosis in B-cell lymphoma and CLL cells [171]. Ibrutinib 
showed significant activity in patients with relapsed CLL or other B –cell malignancies [172]. 
Phase 1b-2 multicenter study with ibrutinib as a single agent on relapsed or refractory CLL 
and small lymphocytic leukemia, with mostly high-risk disease, was conducted [173]. Side 
effects including diarrhea, fatigue, respiratory tract infection and nausea were noted. The 
response was independent of clinical and genetic risk factors including advanced stage 
disease. The ORR was 71% and mostly with PRs. At 26 months, the estimated PFS rate 
was 74% and the OS was 83%. Studies of combining ibrutinib with monoclonal antibodies 
and other agents are ongoing. A phase III randomized trial of relapsed/refractory CLL 
compared ibrutinib with ofatumumab [174]. Ibrutinib showed better responses as compared 
to ofatumumab (43% vs. 4%) and a significantly improved PFS and OS at a median follow 
up of 9.4 months. Ibrutinib monotherapy as a first line treatment produced an ORR of 71% 
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and 13% CR in untreated older patients [175]. Combination of ibrutinib and rituximab 
resulted in 95% ORR and 8% CR in patients with 17p deletion [176]. Three-year follow-up 
of previously treated and naïve CLL and SLL patients receiving ibrutinib as monotherapy 
showed improved responses and durable remissions [177]. Ibrutinib was well tolerated and 
toxicities with longer follow up diminished. In a recent study, Ibrutinib with 
chemoimmunotherapy showed responses. BR-ibrutinib demonstrated ORR of 93.3% 
including 16.7% CR whereas patients treated with ibrutinib-FCR exhibited CR [178]. Despite 
of these impressive responses with ibrutinib in CLL, minimal residual disease-negative 
status has not been achieved and a recent study has identified a mutation in BTK that 
results in an autonomous BCR signaling and could explain the resistance of these patients 
to ibrutinib [179]. Further studies on long-term follow up and utilizing combinations of 
different therapeutic agents with ibrutinib are currently undergoing. 
1.7.4.3 Fostamatinib (R406) 
Syk is another intracellular kinase of BCR signaling pathway affecting downstream 
proteins that are involved in the survival and proliferation of cell. Fostamatinib is a 
reversible inhibitor of Syk and induce apoptosis of CLL cells in vitro [90, 180]. Fostamatinib 
has shown modest clinical activity with minimal toxicity [181]. However, fostamatinib was 
found to have limited specificity to Syk and showed activities against other kinases too [182]. 
GS-9973 is another selective and orally available inhibitor of Syk that has been used in 
previously treated patients with CLL or lymphoma [183]. Another selective inhibitor of Syk 
is P505-15 that has shown activity in vitro as well as in vivo and enhances the activity of 
fludarabine in CLL [184]. 
1.7.4.4 Dasatinib (Sprycel) 
Dasatinib is an oral broad-spectrum BCR/Abl and Src family kinase inhibitor approved for 
up-front therapy of chronic myelogenous leukemia (CML), also shows modest activity in 
CLL with myelosuppression as the main side effect [185, 186]. 
1.7.5 Bcl-2 inhibitors 
The Bcl-2 family proteins are known to regulate apoptosis. The family comprises of Bcl-2, 
Bcl-xL and Mcl-1, they may induce or inhibit apoptosis [187, 188]. Bcl-2 is regarded as a key 
antiapoptotic protein and damage to Bcl-2 has been identified in several cancer and cause 
of resistance to cancer treatments [189-191]. Bcl-2 is up-regulated in CLL cells, possibly due 
to deletion of miRNA regulators [192]. 
1.7.5.1 Oblimersen sodium 
The first such Bcl-2 inhibitor to enter clinical trial in CLL was oblimersen sodium that 
showed modest activity as a single agent with myelosuppression as a predominant side 
effect [193]. Oblimersen sodium has been used in combination with rituximab and 
cyclophosphamide, showing an increase in CR and PR rates [194]. Tumor lysis syndrome 
was reported when used as a single agent. Currently there are no reports on plans for their 
further development. 
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1.7.5.2 ABT-263 (Navitoclax) 
ABT-263 is another agent that inhibits Bcl-2, Bcl-xL and Bcl-w, causing apoptosis in CLL 
cells [195]. ABT-263 demonstrated activity in fludarabine refractory patients in clinical trials 
[196]. This agent had however dose-limiting thrombocytopenia as a major side effect. 
1.7.5.3 ABT-199 (GDC-0199) 
ABT-199 is another specific Bcl-2 inhibitor with higher affinity for Bcl-2 than Bcl-xL [197]. 
Recently a phase I study of ABT-199 in relapsed patients showed an ORR of 77% with 
23% CR and 59% PFS with two years [198]. Neutropenia was the most severe side effect but 
less thrombocytopenia was observed than with ABT-263. Diarrhea, nausea and fatigue 
were the non-hematological side effects affecting one third of patients. Recent data from 
phase Ib study of ABT-199 in combination with rituximab in relapsed patients 
demonstrated 84% objective responses, 36% CRs, MRD negativity and better tolerated 
toxicities [199]. Further studies of ABT-199 as a single agent as well as in combinations are 
currently underway. 
1.7.5.4 Homoharringtonine 
Homoharringtonine is an inhibitor of Mcl-1, an antiapoptotic protein of Bcl-2 family, 
which is upregulated in CLL cells. This inhibitor was originally developed for treatment of 
acute myeloid leukemia and currently used for the treatment of CML, has shown 
significant activity in CLL cells in vitro and will be entering to clinical trials [200]. 
1.7.6 CDK inhibitors 
Cyclin-dependent kinases (CDK) are important regulatory proteins of cell cycle. CDKs can 
be targeted by inhibitors resulting in the induction of programmed cell death in CLL cells 
[201]. CDK inhibitors flavopiridol, dinaciclib, P1446A and CDK-73 have shown preclinical 
activity against CLL cells [202-204]. The CDK inhibitors appear to be active both as single 
agent as well in combinations in relapsed CLL cases but they may not be as effective and 
more toxic than ibrutinib [205]. 
1.7.7 HDAC inhibitors 
Histone deacetylases (HDACs) have been shown to be overexpressed in CLL cells. 
Inhibition of HDAC has resulted in apoptosis of CLL cells by down regulation of Mcl-1 
antiapoptotic protein [206]. HDAC inhibitors may also induce autophagy, which is pro-
apoptotic mechanism in CLL. However, the HDAC inhibitors mocetinostat and vorinostat 
have not induced clinical responses in high-risk CLL patients [207-209]. 
1.7.8 Immunomodulation 
The introduction of immunomodulating drugs represents a major progress in the treatment 
of multiple myeloma and myelodysplastic syndrome (MDS) [210, 211]. 
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1.7.8.1 Lenalidomide 
Lenalidomide is an analog of thalidomide, which in addition to its significant activity in 
multiple myeloma, has also demonstrated to downregulate the production of growth factors 
that are important in the survival and prolongation of CLL cells [212]. Lenalidomide showed 
activity in refractory or relapsed CLL patients with significant overall response rate but no 
evidence of specificity for the 17p resistant patients [213]. Tumor lysis syndrome and other 
life threatening significant toxicities were noticed at a dose of 25 mg/d for three weeks [214]. 
Combination of lenalidomide with monoclonal antibodies and chemotherapeutic agents 
deems another approach but high risk of toxicity remains a major challenge. Phase III study 
of lenalidomide as a potential maintenance agent in CLL is currently undergoing. 
1.7.8.2 CAR-T cells 
Another approach is to use the therapeutic effect of the T cell immune response in 
eliminating CLL cells [215, 216]. The patient’s own T cells are modified to target the 
malignant cells. The T cells out of inhibitory microenvironment may be used to reverse the 
T-cell dysfunction and this has been achieved by using single-chain variable fragment from 
antibody fused with an internal signaling domain to form chimeric antigen receptor (CAR). 
CD19 is the most commonly targeted tumor associated antigen in CLL which is restricted 
only to B cells [217].  
The first trial of three relapsed CLL patients with anti-CD19 CAR-T cells has shown 
impressive results [218]. In a recent update, 14 relapsed patients showed responses. The 
responses were independent of age, TP53 abnormalities and no dose: toxicity or dose: 
response relationships were noted at the dose ranges used. The expanded CAR-T cells were 
able to last for at least three years [219]. Fever, hypotension, deterioration in mental status 
occasionally and neurological changes were the observed side effects.  
Many challenges are yet to be addressed including better efficacy, less toxicity and 
capability to produce large number of CAR-T cells. Reason for CAR-T cells failure is not 
completely understood but could be associated with down-regulation of tumor associated 
antigens and may be the inability of CAR-T cells to recycle effector functions owing to 
tumor environment [217]. Acceptable toxicity and producing CAR-T cells are the main 
targets in future to achieve.  
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2 RECEPTOR TYROSINE KINASES (RTKs) 
RTKs are cell surface glycoproteins with enzymatic activity which regulate various 
important functions  [220, 221]. The receptors play a vital role in cellular processes as 
differentiation, cell-cell interactions, survival, proliferation, metabolism, migration and 
signaling. RTKs are classified into 20 different receptor tyrosine kinase families which 
consist of 58 members [222] as shown in the Figure 4. 
 
 
Figure 4. Cell signaling by receptor tyrosine kinases. Human receptor tyrosine kinases (RTKs) contain 
20 subfamilies, shown here schematically with the family members listed beneath each receptor. 
Structural domains in the extracellular regions, identified by structure determination or sequence analysis, 
are marked according to the key. The intracellular domains are shown as red rectangles. 
Reprinted from Cell, 141(7):1117-1134. 2010, Lemmon M et al, “Cell signaling by receptor tyrosine kinases”.  
Copyright (2015), with permission from Elsevier. 
 
The structure of RTKs consists of three parts, the extracellular part containing the ligand 
binding domain, a transmembrane part and an intracellular part containing the TK domain 
involved in downstream signaling.  
Figure 5 shows RTKs expressed in CLL. 
20 Receptor tyrosine kinase (RTKs) 
 
 
Figure 5. Tyrosine kinase network in CLL. Leukemic B cells from CLL patients express multiple 
RTKs, which may directly or indirectly participate in the “Cell Survival” signaling network. As most of 
the RTK signaling pathways share common intermediate signaling components, for example, Src and 
PI3K/AKT, we believe that in this “RTK Network,” one RTK plays the role of the “Predominant RTK” 
while others play a secondary role, likely depending on the risk factors of the cells. In CLL, upon binding 
specific ligands, these RTKs may activate multiple signaling intermediates, including Src, Syk, 
Grb2/PI3K, Ras/Raf, and PLC-γ, leading to activation of the downstream effector signaling components: 
for example, AKT, MAPK, PKC, or STATs, which ultimately activates various specific target genes, 
resulting in cell survival, proliferation, and apoptosis resistance. However, expression of constitutively 
active RTKs in CLL B cells results in uncontrolled activation of the downstream signaling molecules, 
leading to increased cell survival and apoptotic resistance to therapeutic agents. One such constitutively 
active RTK in CLL we detected was Axl. 
Springer and Advanced in Experimental Medicine and Biology; Chronic Lymphocytic Leukemia, Malek S, 2013, 
Chapter:” Critical Signal Transduction Pathways in CLL”, Ghosh AK et al, pp 215-239, Figure 10.3. Reproduced 
with kind permission from Springer Science and Business Media. 
 
Activation of the RTKs by ligand binding and dimerization of the extracellular part initiates 
signaling that regulates various cellular functions [223]. Aberrant expressions of different 
RTKs in various malignancies are summarized in Table 3  [224]. Mutations of RTKs or their 
overexpression have been described in many human cancers and are considered as 
therapeutic targets [220]. Abnormal RTK activation involved in carcinogenesis e.g. may 
result from overexpression, amplification, mutations or chromosomal translocation  [225-227]. 
Some of the deregulated RTKs that have been identified in cancers as epidermal growth 
factor receptor (EGFR), fibroblast growth factor receptor (FGFR), vascular endothelial 
growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and 
receptor tyrosine kinase orphan receptor 1 (ROR1). These deregulated RTKs might be 
targeted by monoclonal antibodies against the extracellular part and by kinase inhibitors 
against the intracellular kinase-containing domain [228].  
Receptor tyrosine kinase (RTKs) 21 
 
Table 3. Expression of oncogenic RTKs in cancer 
RTK Chromosome 
location 
Normal function Malfunction leading  
to overexpression 
Malignancy (examples) 
ROR1 1p31.3 ED, NSD Unknown CLL, ALL, AML, MCL, HCL, 
melanoma, prostate, lung, breast, 
pancreas, colon, ovarian, uterus 
cancers 
ROR2 9q22.31 ED, NSD Mutations Melanoma, medulloblastoma, testicular 
cancer, gastrointestinal stromal tumor, 
hepatocellular carcinoma, colon 
cancer, renal cell carcinoma, 
osteosarcoma, prostate carcinoma
ALK 2p23 NSD Translocation (t2:5) 
Overexpression 
NSCLC, colorectal cancer, breast 
cancer, oesophageal cancer (squamous 
cell), renal cell cancer
ROS1 6q22 NSD  Deletion, inversion, 
translocation 
NSCLC, cholangiocarcinoma, ovarian 
cancer, gastric cancer, colorectal 
cancer 
RET 10q11.2 NSD Mutations NSCLC, medullary thyroid carcinoma 
NTRK1 
(TrkA) 
1q21-22 Development and maturation of central 
and peripheral nervous system 
Translocation Colorectal cancer, papillary thyroid 
cancer, lung adenocarcinoma, breast 
cancer, oral squamous cell carcinoma 
NTRK2 
(TrkB) 
 Development and maturation of central 
and peripheral nervous system
Translocation Neuroblastoma, astrocytoma, oral 
squamous cell carcinoma
NTRK3 
(TrkC) 
15q25 Development and maturation of central 
and peripheral nervous system 
Translocation Neuroblastoma, breast cancer 
PDGFRA 4q12 ED Mutations Lung adenocarcinoma, gastrointestinal 
stromal tumors 
PDGFRB 5q32 Regulation of embryonic development, 
cell proliferation, survival, differentiation, 
chemotaxis, migration and blood vessel 
development 
Mutations Gastrointestinal stromal tumors, 
glioblastoma 
FGFR1 8p12 Regulation of embryonic development, 
cell proliferation, differentiation and 
migration 
Mutations Squamous cell lung cancer, breast 
cancer 
FGFR2 10q26 ED Mutations, 
overexpression 
Squamous cell lung cancer, lung 
adenocarcinoma, breast cancer, thyroid 
cancer, prostate cancer, 
cholangiocarcinoma, astrocytoma
FGFR3 4p16.3 Normal skeleton development Mutations Bladder cancer, squamous cell 
carcinoma (lung, head and neck) 
MET 7q31.2 Gastrulation, development and migration 
of muscles and neuronal precursors, 
angiogenesis and kidney formation 
Mutations Hepatocellular carcinoma, CLL, breast 
cancer, pancreatic cancer, lung cancer, 
gastric adenocarcinomas 
Axl 19q13.1 ND Unknown Lung cancer, colon cancer, breast 
cancer, AML, CML, esophageal, 
thyroid cancer, gastrointestinal stromal 
tumors, astrocytoma-glioblastoma
IGF1R 15q26.3 Embryonic and fetal development Mutations CLL, breast cancer, oral squamous cell 
carcinoma cells. gastrointestinal 
stromal, squamous-cell laryngeal 
cancer tumors, hepatocellular 
carcinoma, pancreatic cancer 
IGF2R 6q25.3 Embryonic and fetal development Mutations Squamous cell carcinoma, breast 
cancer, prostate cancer, hepatocellular 
carcinoma, colorectal carcinoma, 
NSCLC, pancreatic cancer
EGFR1 
(ERBB1) 
7p11.2 ED Mutations Breast cancer, hepatocellular 
carcinoma, head and neck squamous 
cell carcinoma 
EGFR2 
(ERBB2) 
17q12 ED Mutations Breast cancer, gastric adenocarcinomas 
EGFR3 
(ERBB3) 
12q13.2 ED Mutations Breast cancer  
EGFR4 
(ERBB4) 
2q34 ED Mutations Breast cancer, melanoma 
VEGFR1 
(FLT1) 
13q12.3 ED Mutations Ovarian cancer, NSCLC, colorectal 
carcinoma  
22 Receptor tyrosine kinase (RTKs) 
 
RTK Chromosome 
location 
Normal function Malfunction leading  
to overexpression 
Malignancy (examples) 
VEGFR2 
(KDR) 
4q12 ED Mutations Renal cell carcinoma, hepatocellular 
carcinoma 
VEGFR3 
(FLT4) 
5q35.3 ED Mutations  
FLT3 13q12.2 Hematopoiesis  Mutations AML, acute promyelocytic leukemia 
KIT 4q12 Hematopoiesis, stem cell maintenance, 
gametogenesis, mast cell development, 
migration and function, and in 
melanogenesis 
Mutations AML, melanoma, ovarian carcinoma, 
gastrointestinal stromal tumors 
RON 
(MST1R) 
3p21.31 Regulates many physiological processes 
including cell survival, migration and 
differentiation 
Mutations Pancreatic cancer, breast cancer, 
NSCLC, laryngeal squamous cell 
carcinoma, head and neck squamous 
cell carcinoma 
INSR 19p13.2 Metabolic actions of insulin Mutations Colorectal cancer, prostate cancer
INSRR 1q23.1 Metabolic actions of insulin Mutations Neuroblastomas 
CCK4 
(PTK7) 
6p21.1 ED Mutations Squamous cell carcinoma, small cell 
lung cancer, breast cancer, gastric and 
colon cancer, AML 
EPHA1 7q35 NSD Mutations NSCLC, prostate cancer, esophageal 
squamous cell carcinoma 
EPHA2 1p36.13 NSD Mutations Hepatocellular carcinoma. colorectal 
cancer, osteosarcoma, breast cancer 
EPHA3 3p11.1 NSD Mutations Glioblastoma, lung cancer, melanoma, 
ALL, T-cell leukemia, hodgkins 
lymphoma 
EPHA4 2q36.1 NSD Mutations NSCLC, gastric cancer 
EPHA5 4q13.1 NSD Mutations Breast cancer, hepatocellular 
carcinoma, ALL 
EPHA6 3q11.2 NSD Mutations -
EPHB1 Xq13.1 NSD - NSCLC, cervical cancer, ovarian 
cancer 
EPHB2 13q33.3 NSD - Cervical cancer, breast cancer
EPHB3 3q27.1 NSD - NSCLC, breast cancer, colorectal 
cancer 
EPHB4 7q22.1 NSD - Breast cancer, melanoma, glioma
MER 2q13 Survival, migration, differentiation, and 
phagocytosis of apoptotic cells 
Mutations Glioblastoma, hepatocellular 
carcinoma, astrocytoma 
TYRO3 15q15.1 Cell survival, migration and 
differentiation 
Mutations Colon cancer, melanoma, thyroid 
cancer, breast cancer 
TIE 1p34.2 Regulation of angiogenesis Mutations Glioblastoma 
TEK 9p21.2 Regulates angiogenesis, endothelial cell 
survival, proliferation, migration, 
adhesion and cell spreading, 
reorganization of the actin cytoskeleton, 
but also maintenance of vascular 
quiescence 
Mutations Bladder cancer, glioblastoma, AML 
RYK 3q22.2 Neuron differentiation, axon guidance, 
corpus callosum establishment and 
neurite outgrowth 
Translocation, 
mutations 
CML, ovarian cancer 
DDR1 6p21.33 Regulates cell attachment to the 
extracellular matrix, remodeling of the 
extracellular matrix, cell migration, 
differentiation, survival and proliferation
Mutations NSCLC, breast cancer, AML, ovarian 
cancer, hepatocellular carcinoma 
DDR2 1q23.3 Regulates cell differentiation, remodeling 
of the extracellular matrix, cell migration 
and cell proliferation 
Mutations Head and neck squamous cell 
carcinoma, NSCLC, lung cancers, 
CML, breast cancer 
LTK 15q15.1 ND Mutations Gastric cancer, lymphomas, leukemias 
MUSK 9q31.3 NSD Mutations Ovarian cancer 
ROR: receptor tyrosine kinase-like orphan receptor, ED: embryonic development, NSD: nervous system development, CLL: chronic lymphocytic 
leukemia, ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, HCL: hairy cell leukemia, NSCLC: non-small cells lung carcinoma, 
NTRK: neurotrophic tyrosine kinase, PDGFR: platelet- derived growth factor receptor, FGFR: broblast growth factor receptor, ND: normal 
development, CML: chronic myeloid leukemia, INSR: insulin receptor, EGFR: epidermal growth factor receptor, VEGFR: vascular endothelial growth 
factor receptor, CCK: colon carcinoma kinase, RYK: receptor related to tyrosine kinases, DDR: discoidin domain receptor, LTK: leukocyte tyrosine 
kinase, MuSK: muscle-specic kinase..
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2.1 ROR family of receptor tyrosine kinase 
The receptor tyrosine kinase orphan receptor (ROR) family consists of ROR1 and ROR2 
previously known as neurotrophic tyrosine kinase receptors 1 and 2 (NTRKR1) and 
(NTRKR2) respectively [229]. ROR1 and ROR2 belong to type I transmembrane proteins 
that are evolutionary highly conserved among different species including humans, mice, 
rats, chickens, zebra fish, roundworms and fruit flies. 
The structure of ROR family RTKs contains the extracellular part with the ligand 
binding domains, a transmembrane part that anchors the receptor in plasma membrane, and 
an intracellular part expressing a kinase domain for signal transmission as shown in Figure 
6. The extracellular ROR part consists of the immunoglobulin (Ig)-like domain, Frizzled-
like cysteine-rich domain (CRD) and a membrane-proximal kringle (KNG) domain. The 
intracellular part of ROR contains a tyrosine kinase (TK) domain, proline-rich domain 
(PRD) and a serine/threonine rich domain [230]. 
 
Figure 6. Structure of ROR 
receptor tyrosine kinases 
(RTKs) in different species. 
Domain organization of ROR 
proteins in human (hROR1, 
hROR2), mouse (mRor1, 
mRor2), C. elegans (CAM-1) 
and Drosophila (dROR). The 
N-terminal extracellular 
domain (ECD) is above and 
the intracellular domain 
(ICD) is below the double 
line representing the plasma 
membrane. 
Reprinted from Trends in Cell 
Biology, 18(11):536-44, 2008, Green 
JL et al, “Ror receptor tyrosine 
kinases: orphans no more”. 
Copyright (2015), with permission 
from Elsevier.  
 
 
 
 
 
2.2 Structure of ROR1 
Human ROR1 and ROR2 (hROR1 and hROR2) share 58% identity in amino acids 
sequence and 68% in the kinase domains. Amino acids sequence identity is highly 
conserved among different species within the ROR1 and ROR2 subgroups respectively. A 
97% amino acid sequence identity of human and mouse ROR1 (hROR1 and mROR1) has 
been noted and 92% for human and mouse ROR2 [231, 232]. Other mammalian ROR proteins 
have the same extracellular region containing Ig-like domain, CRD and KNG domains, 
24 Receptor tyrosine kinases (RTKs) 
 
transmembrane and an intracellular part containing TK domain, proline-rich and two 
serine/threonine motifs. 
Human ROR1 is located on chromosome 1 (1p31.3) with a protein size of 937 amino 
acids and molecular weight of approximately 105 kDa. The human ROR2 is located on 
chromosome 9 (9q22) with a protein size of 943 amino acids and a molecular weight of 
approximately 104.7 kDa. 
2.2.1 Extracellular part of ROR1 
2.2.1.1 Signal peptide 
ROR family of RTKs possesses a short peptide sequence of about 20-30 amino acids at the 
N-terminal. The signal peptide directs the protein to the endoplasmic reticulum for further 
maturity and secretion. Then it is recognized by signal recognition particle (SRP) and 
cleaved by signal peptidase [232, 233]. 
2.2.1.2 Immunoglobulin-like domain (Ig) 
The Ig-like domain is at the far end of the extracellular part consisting of 106 amino acids 
residues in human ROR1 and 91 in ROR2. The precise role of the Ig-like domain is 
unknown but may be involved in protein and ligand interactions as well as interfering with 
the CRD and KNG domains [234]. 
2.2.1.3 Cysteine-rich domain (CRD) 
The CRD domain consists of 135 amino acids sequence, which is located between the Ig-
like and KNG domains. 10 conserved cysteine residues that form five disulfide bonds 
characterize the CRD domain. The CRD domain is similar to the Wnt binding domain of 
Frizzled receptors and is suggested as one of the ligand binding domain of ROR1. ROR1 
has been shown to physically interact with Wnt5a, resulting in increased survival of CLL 
cells in vitro by activating NF-κB [235]. 
2.2.1.4 Kringle domain (KNG) 
The KNG domain is located in close proximity to the plasma membrane consisting of 79 
amino acids and is highly conserved among different species. The KNG domain might 
serve as a recognition binding site for Wnt regulatory proteins and other ROR1 ligands [229]. 
The ROR family is the only RTK family that contains a KNG domain with the exception of 
Torpedo Musk [232]. 
2.2.2 Intracellular part of ROR1 
2.2.2.1 Tyrosine kinase (TK) domain 
ROR family proteins are the most divergent within the RTK family containing only 21 of 
the 40 consensus residues in the TK compared to other RTKs  [236]. The functional role of 
the ROR1 TK domain is a matter of intense debate. Early studies showed that ROR1 
possessed weak to a very moderate kinase activity [230, 237] but recently a study showed that 
ROR1 TK domain was sufficient to phosphorylate c-SRC in NIH3T3 cells [238]. Now we 
Receptor tyrosine kinases (RTKs) 25 
 
know that ROR1 is constitutively phosphorylated at tyrosine residues in CLL cells, which 
is dephosphorylated after treatment with ROR1 monoclonal antibodies against CRD and 
KNG domains [239]. 
2.2.2.2 Serine/threonine-rich domains 1 & 2 (S/TRD1 & S/TRD2) and proline-rich domain 
(PRD) 
Two serine/threonine-rich domains (S/TRD), which are separated by a proline-rich domain 
(PRD) have been described in ROR RTK. S/TRDs or PRD have not been found in other 
RTKs. These cytoplasmic domains are important as they contain potential phosphorylation 
sites. The SH2 and SH3 recognition motifs interact with mediators of different downstream 
signaling molecules [240, 241]. ROR1 is also phosphorylated at 786, 789, 822, and 836 
tyrosine residues that contribute to phosphorylation of tyrosine in the kinase domain by 
SRC kinases. The consensus SH3 motifs facilitate binding of SRC to the proline-rich 
domain, which ultimately results in ROR1 phosphorylation. Deletion of PRD as well as 
SRC prevented phosphorylation of ROR1 within the kinase domain [242]. 
2.3 ROR tyrosine kinase activity 
ROR kinase activity has been discussed. Earlier studies indicated a strong autocatalytic 
kinase activity for ROR2 but a weak to moderate for ROR1 [230, 237]. In a recent study, 
ROR1 TK domain was shown to possess kinase activity [238]. However, in another study 
ROR1 was suggested to be a pseudokinase without kinase activity in COS-7 cells [242]. A 
pseudokinase is a kinase with no or very limited enzymatic activity and may not be capable 
to phosphorylate the substrate due to amino acid substitutions in critical residues that 
regulate the enzymatic activity of tyrosine kinases [243]. However, specific ROR1 silencing 
and targeting ROR1 by monoclonal antibodies resulted in the apoptosis of CLL cells [244, 
245]. This indicates the crucial role of ROR1 in survival of CLL cells. 
2.4 Expression and functions of ROR1 during development 
Several studies using in situ hybridization and mutant knockout mice models indicated the 
involvement of ROR during skeletal, cardiorespiratory and neurological development. 
mROR1 seemed to be limited to the cephalic mesenchyme and neural crest cells whereas 
mROR2 expression was noted in both neural and non-neural cells during development [246]. 
ROR1 was tightly down regulated after birth [230, 237]. 
Human ROR1 expression was found in fetal heart, lung, kidney and low expression in 
placenta, pancreas and skeletal muscle [231]. ROR1 expression at mRNA level was not 
found in various normal hematopoietic and non-hematopoietic tissues but a low expression 
was seen in pancreas and adipose tissues. Normal adult tissues tested for ROR1 protein did 
not show expression in majority of samples except testis, uterus, lung, bladder and colon, 
where a low expression was noticed [247].  
ROR1 protein was detected at an intermediate stage of the normal B-cell maturation in 
the bone marrow (pre-BII stage), where cells proliferated following internalization of the 
pre-B-cell receptor complex. This process was essential for the development to an 
immature B-cell stage [248]. 
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Knockdown studies for ROR1 and ROR2 have been conducted in mice to evaluate 
their functions. Mice with homozygous knockout of mROR2 resulted in shortened limbs, 
cyanosis, septal defects of the heart. The mice died within six hours after birth due to 
respiratory defects [249]. Mice with homozygous knockout of mROR1 developed perinatally 
lethal defects because of respiratory dysfunction but these mice did not show pronounced 
heart or skeletal abnormalities [250]. ROR1 and ROR2 double deficient mice died shortly 
after birth due to respiratory problems associated with incomplete expansion of lung alveoli 
[234, 249, 250]. The expression of ROR2 was sustained in hippocampus and caudate putamen in 
the late stages of embryonic development but mROR1 was not detectable [251]. 
2.5 ROR1 and cancer 
ROR1 expression has been seen in various blood and solid malignancies. The low ROR1 
expression in normal adult tissue and high expression in cancer have encouraged 
researchers to investigate the functional advantage conferred by ROR1 and to explore 
ROR1 for targeted therapy in cancer [245, 247, 252, 253]. In Table 4, the expression of ROR1 and 
its association with progression in different malignancies is described [224]. 
 
Table 4. Overexpression of ROR1 in malignancies. 
Malignancy Constitutively phosphorylated ROR1 
Association to disease 
progression 
CLL + + 
B-ALL NI + 
CML NI NI 
AML NI NI 
Hairy cell leukemia NI NI 
Mantle cell lymphoma NI NI 
Pancreatic cancer NI + 
Prostate cancer NI NI 
Colon cancer NI NI 
Bladder carcinoma NI NI 
Ovarian cancer NI + 
Testicular cancer NI NI 
Uterus NI NI 
Adrenal carcinoma NI NI 
Breast cancer + + 
Lung cancer +  + 
Melanoma + NI 
CLL: chronic lymphocytic leukemia, B-ALL: B-cell acute lymphoblastic leukemia, NI: no information,  
CML: chronic myeloid leukemia, AML: acute myeloid leukemia. 
2.5.1 ROR1 in hematological malignancies 
ROR1 expression was initially identified in chronic lymphocytic leukemia and later on in 
other malignancies. In 2001, two independent gene-profiling studies identified high ROR1 
expression (45-fold increase) in CLL as compared to normal mature B-lymphocytes [37, 254]. 
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ROR1 protein expression has been shown in CLL [235, 247, 255] and also in other malignancies 
such as acute lymphocytic leukemia (ALL) [256, 257], breast cancer [258], renal cell carcinoma 
[259], melanoma [260], lung adenocarcinoma [238] and other lymphoid and myeloid 
malignancies [255, 257, 258, 260-263]. 
The number of ROR1 receptors on the surface of CLL cells was estimated to be in the 
range of 10,000 per cell [235, 255] which should be enough to be targeted by monoclonal 
antibodies [239, 245]. ROR1 expression in CLL increased during disease progression. STAT3 
is constitutive phosphorylated in CLL and has been shown to bind to the promoter region 
of ROR1 in CLL [264]. Maybe STAT3 is involved in the expression of ROR1. ROR1 
expression could also be induced by IL-6 in a STAT3 dose-dependent manner [265]. 
Wnt5a is suggested to be one of the ligands for ROR1. Wnt5a was shown to bind to 
ROR1 in the HEK cells inducing activation of NF-κB. Co-culturing of Wnt5a significantly 
increased survival of CLL cells compared to those without Wnt5a. The Wnt5a dependent 
survival of CLL cells was inhibited by ROR1 antisera [235]. 
ROR1 has been shown to be phosphorylated at tyrosine and serine residues in CLL and 
also in other malignancies. Wnt5a could maintain phosphorylation of ROR1 [258]. ROR1 
phosphorylation varied from patient to patient in CLL. High ROR1 phosphorylation 
intensity was found in progressive compared to non-progressive CLL. The same pattern 
was observed in other malignancies including breast, lung and ovarian cancer cells with an 
aggressive course [239]. Furthermore, ROR1 expression at the protein level was significantly 
higher in aggressive tumors [253]. Collectively these data may suggest that the expression 
pattern of ROR1 is related to aggressiveness. 
ROR1 was highly expressed in some but not in all cases of multiple myeloma, diffused 
large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), follicular lymphoma 
(FL) and mantle cell lymphoma (MCL) at gene level as well as at the protein level [252]. 
High ROR1 expression has also been shown in ALL and specifically those with 
t(1;19)(q23;p13) translocation. ROR1 was important for survival of ALL cells with 
t(1;19)(q23;p13) translocation when screened for critical tyrosine kinases in the 
pathogenesis of ALL [266]. 
2.5.2 Expression of ROR1 in solid tumors 
ROR1 expression has been shown in various solid tumors. The expression pattern varied 
from moderate to high depending on the type of cancer. Moderate ROR1 staining was 
observed in majority of prostate, testicular, uterine, ovarian, lymphoma, adrenal and 
melanoma cancers [253]. Strong ROR1 staining was found in 30% or greater of primary 
samples in the lung, colon and pancreatic cancers [246]. In lung adenocarcinoma, TITF1 has 
been shown to regulate ROR1 expression. ROR1 up-regulation was linked with the 
potentiation of EGF ligand-induced EGFR signaling, phosphorylation and activation of c-
SRC [238]. 
ROR1 expression was also detected in all melanoma cell lines at mRNA level as well 
as protein level as assessed by Western blot and RT-PCR in addition to surface ROR1 
staining by flow cytometry. Knockdown of ROR1 in melanoma cell lines induced 
apoptosis [261]. ROR1 was shown to be phosphorylated at both tyrosine and serine residues. 
Monoclonal antibodies against ROR1 induced apoptosis [261]. ROR1 and ROR2 were shown 
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to be inversely expressed in melanoma cells indicated that they may negatively regulate 
each other [260]. Hypoxia resulted in a shift of ROR1 positive cells to an aggressive ROR2 
phenotype in melanoma cells. The switch to the ROR2 positive phenotype resulted in 10-
fold decrease in sensitivity to BRAF inhibitors. 
In breast cancer, ROR1 was shown to be expressed in human neoplastic cells but 
absent in stromal cells. ROR1 overexpression in breast cancer was linked to aggressive 
disease. Breast cancer cell lines with strong ROR1 expression were more aggressive and 
invasive but declined in non-migrating cells [258]. ROR1 silencing through specific ROR1 
siRNA resulted in down-regulation of ROR1 expression in human breast cancer cell lines 
and impairment of growth in immunodeficient mice. ROR1 was also shown to activate 
PI3K mediated AKT and CREB signaling pathways by interacting with casein kinase 1 
(CK1) [258]. Wnt5a increased the survival of ROR1 expressing breast cancer cells, 
confirming the notion of Wnt5a as a ligand for ROR1 [258, 267]. 
High levels of ROR1 expression in patients and cell lines were linked to genes 
contributing to epithelial-mesenchymal transition (EMT) such as ZEB1 and vimentin and 
inversely related to adherent junction proteins. ROR1 expression was high in breast 
adenocarcinomas with high level of EMT related genes and with a high capacity to 
metastasize. Silencing of ROR1 in the triple negative breast cancer cell line MDA-MB321 
by small hairpin (sh) RNA reduced in vitro cell migration as well as bone and lung foci 
xenografts [267]. Knockdown of ROR1 in triple negative breast cancer cells also reduced the 
EMT genes like SNAI1, SNAI2, ZEB1 and vimentin [267]. Similarly, ROR1 transfected 
MCF-7 cell lines showed low level expression of adherent junction proteins like E-cadherin 
and CK-19 which contribute to homing of cells at proliferation sites but ROR1 transfection 
did not change expression levels of SNAI1, SNAI2 and vimentin  [267]. 
2.6 Roles of ROR1 
ROR1 localization to the nucleus may suggest that it might act as transcription factor to 
activate genes involved in tumorigenesis [239, 268]. Stimulation of multiple myeloma cell lines 
by IL-6 resulted in phosphorylation of signal transducer and activator of transcription factor 
3 (STAT3) and up-regulation of ROR1 indicating a possible role of STAT3 in the 
activation of ROR1 [269]. The ROR1 promoter region contains γ-interferon activation 
sequence like elements, which are activated by STAT3 [270]. STAT3 has also been shown to 
induce Wnt5a expression  [271, 272]. Based on these findings, it is suggested that STAT3 may 
activate ROR1 and Wnt5a, which may promote cell survival, growth and migration through 
Wnt5a binding to the ROR1 promoter region.  
A schematic depiction of ROR1 signaling is shown in Figure 7. 
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Figure 7. A schematic proposed model for ROR1 signaling. The ROR1 receptor tyrosine kinase 
recruits canonical and non-canonical signaling pathways for cell survival and invasion. A central pathway 
is the PI3K/AKT/mTOR pathway which activates the CREB transcription factor for nucleus 
translocation. ROR1 kinase-dependent SRC activation is a key initiating event. Proteins like ROR1, 
STATs and CREB might act as transcription factors and bind to ROR1 promoter region to enhance the 
expression of the ROR1 gene. Phosphate groups are denoted as green circles. 
Reprinted from Seminars in Cancer Biology, 29:21-31, 2014, Hojjat-Farsangi et al, “The receptor tyrosine kinase 
ROR1 – An oncofetal antigen for targeted cancer therapy”. Copyright (2015), with permission from Elsevier. 
 
In CLL, ROR1 has been shown to undergo extensive N-linked glycosylation modifications. 
Several ROR1 isoforms with different electrophoretic mobility in the range of 100-130 kDa 
have been identified probably as a result of posttranslational modifications  [273]. Prevention 
of ROR1 glycosylation resulted in the altered surface expression of the fully mature 130 
kDa ROR1 isoform and formation of filopodia in HEK cell lines suggesting a role of ROR1 
in cell migration and metastasis. 
ROR1 signaling pathways have not been fully recognized in cancer. PI3K/AKT 
pathway was shown to be activated and related to ROR1 after stimulation with Wnt5a in 
breast cancer cell. Knockdown of ROR1 by siRNA or absence of Wnt5a inhibited growth 
of breast cancer cells [258]. Our preliminary data showed that treatment of ROR1 positive 
pancreatic carcinoma cell lines with anti-ROR1 mAbs or tyrosine kinase inhibitors against 
ROR1 dephosphorylated ROR1 and downstream signaling proteins as SRC, PI3K, AKT, 
mTOR and CREB subsequently leading to apoptosis. 
ROR1 has been shown to be related to BCR signaling in a counterbalance manner for 
the survival of ALL cells  [266]. Downregulation of pre-BCR signaling and ROR1 induced 
permanent dephosphorylation of AKT and enhanced cell cytotoxicity. However, 
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downregulation of either ROR1 or BCR signaling alone did not cause the same effect, 
suggesting a link between ROR1 and BCR signaling. 
ROR1 may also play a role in leukemogenesis of CLL cells by interacting with the T-
cell leukemia antigen (TCL1), which is an activator of AKT. Co-expression of ROR1 and 
TCL1 enhanced leukemogenesis resulting in phosphorylation of AKT, cell proliferation 
and resistance to apoptosis. Down-regulation of ROR1 by anti-ROR mAbs reduced AKT 
activity and loss of tumorigenic characteristics in a syngeneic mice model [274]. 
Our preliminary data showed involvement of MET and the SRC oncogene in 
phosphorylation of ROR1. Phosphorylation of ROR1 at tyrosine residues 641 and 646 in 
the TK domain of ROR1 which was important for survival of the cells  [239]. SRC dependent 
phosphorylation of ROR1 was crucial for cell invasion and specific inhibition of SRC 
activity by saracatinib induced impaired cell invasion but not proliferation [275]. 
Based on current data, ROR1 is suggested to be involved in recruiting different 
signaling proteins, transcription factors and activate signaling pathways, which ultimately 
result in high survival, proliferation and metastasis. The initial activation of ROR1 may be 
different in various malignancies but signaling through the PI3K/AKT/mTOR axis seems 
to be important. This pathway may be switched on by GTPases followed by SRC 
phosphorylation and subsequently binding of SRC to ROR1. Axl, MET, EGFR but other 
tyrosine kinases may also be involved in the activation of ROR1 [238, 275, 276]. Activation of 
ROR1 may then activate and upregulate various genes involved in growth, migration and 
metastasis [267]. Further studies are needed to fully understand the signaling pathways 
affected by ROR1. 
2.7 Isoforms of ROR1 in cancer 
The full length ROR1 with a molecular weight of 105-130 kDa has been identified in all 
malignancies positive for ROR1  [239, 242, 245]. In addition, a truncated isoform of ROR1 (t-
ROR1) without extracellular and transmembrane parts was also identified in neural tissues  
[231]. mRNA encoding the t-ROR1 was found in fetal and adult central nervous system 
(CNS), human leukemia, lymphoma cell lines and other human cancers originating from 
the neuroectoderm. ROR1 encoded by 6kb mRNA was also noted in normal human lung, 
kidney and heart [231]. A neurogenic teratocarcinoma cell line (NTera2) showed the 
expression of a 2373 nucleotide transcript translating to a 388 amino acids protein that was 
identical to the cytoplasmic C-terminal of ROR1 (ROR1-201, ENSP00000441637). A 
splice variant of a 50 kDa ROR1 was also found [247]. Another ROR1 isoform with a 
molecular weight of 260 kDa has also been identified by our group which may represent 
dimerized ROR1 [239]. The 260 kDa ROR1 isoform could represent homodimerized ROR1 
or heterodimerization with ROR2 or other receptors. ROR1 and EGFR were shown 
physically bound to each other in lung adenocarcinoma [238]. We have also identified a 64 
kDa ROR1 in CLL cells which was mainly localized to the nucleus [239] suggesting that 
ROR1 may act as transcription factor [268]. The predominant full length ROR1, glycosylated 
and mature isoform 130 kDa was found to be more abundant in progressive than in non-
progressive CLL  [239]. Different isoforms of ROR1 need further investigation to assign 
them to different functions.  
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2.8 ROR1 as therapeutic targets in cancer 
ROR1 like other oncogenic RTKs might be targeted in cancer. There are two main 
strategies; targeting the extracellular part of the receptor by monoclonal antibodies or by 
tyrosine kinase inhibitors directed against the intracellular kinase domain (Figure 8). In 
Table 5, current tyrosine kinase inhibitors targeting different RTKs are summarized  [277]. 
Targeting the extracellular region of RTK by mAbs may disrupt the cytoplasmic kinase 
signaling by neutralization of the ligand, hampering the ligand binding, internalization of 
the receptor or by interacting with immune effectors targeting the tumor cells. Different 
RTKs HER-2, EGFR, VEGFR and VEGF and their ligands have been targeted in various 
cancers by mAbs. Trastumuzab was the first approved antibody against HER-2 for the 
treatment of breast cancer patients [278]. Pertuzumab is another antibody approved against 
HER-2 to prevent dimerization of HER-2 with members of EGFR family. Similarly, 
tyrosine kinase inhibitors against the intracellular kinase domain in various cancers have 
been designed and approved for clinical use; gefitinib [279] and erlotinib [280] against EGFR 
and lapatinib [281] against HER2. 
 
MAb
Apoptosis, Necrosis
Differentiation 
Proliferation
Invasion
Mab+TKI TKI  
Figure 8. Strategies to target the 
receptor tyrosine kinase ROR1. 
Monoclonal antibodies (mAbs) and 
small molecules (tyrosine kinase 
inhibitor TKI) (red circles) may 
interfere with cell proliferation, 
differentiation, migration, metastasis 
and invasion as well as induction of 
cell death by apoptosis or necrosis. 
Dual blockage by mAbs and TKI 
may further augment the anti-tumor 
effects as has been shown for anti-
EGFR mAb/gefitinib and anti-HER2 
mAb/lapatinib combinations. 
 
Reprinted from Seminars in Cancer 
Biology, 29:21-31, 2014, Hojjat-
Farsangi et al, “The receptor tyrosine 
kinase ROR1 – An oncofetal antigen for 
targeted cancer therapy”. Copyright 
(2015), with permission from Elsevier 
Combination approach, where the extracellular part of RTK is targeted by mAbs and the 
intracellular kinase domain by tyrosine kinase inhibitors, has shown synergistic effects in 
preventing the tumor growth and proliferation of cancer cells. Treatment of xenograft mice 
expressing HER-2 with trastuzumab and lapatinib resulted in significant tumor growth 
inhibition [282]. Similarly treatment of colon cancer cell lines expressing EGFR with 
cetuximab and gefitinib prevented proliferation and induced apoptosis [283]. Targeting of 
HER-2 by trastuzumab and lapatinib has shown better clinical activity than either alone in 
HER-2 positive breast cancer patients [284, 285]. 
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Table 5. Tyrosine kinase inhibitors (TKIs) targeting RTKs. 
Name Developed by Trade 
name 
Chemical 
formulation 
Mol. 
mass 
(g/mol)
Selective  
target 
IC50  
(nM/L)
*
 
Appr.  
for  
treatm. 
Malignancies 
(examples) 
Afatinib Boehringer Ingelheim 
Pharmaceuticals 
Gilotrif C24H25ClFN5O3 485.94 HER2, 
EGFR, 
HER4 
14, 0.5, 1 + NSCLC, squamous 
cell carcinoma of the 
head and neck, breast 
cancer 
Canertinib Pfizer - C24H25ClFN5O3 485.94 EGFR, 
HER2, 
HER4 
0.8,19, 7  Head and neck, 
breast, and NSCLC, 
ovarian cancer 
Cediranib AstraZeneca Pty Ltd Recentin C25H27FN4O3 450.505 VEGFR 1 - NSCLC, kidney and 
colorectal cancer 
CP-673451 Pfizer - C24H27N5O2 417.5 PDGFR 1 - NSCLC, colon 
carcinomas, 
glioblastoma 
Crizotinib Pfizer Xalkori C21H22Cl2FN5O 450.337 MET 11 + NSCLC, anaplastic 
large cell lymphoma, 
neuroblastoma 
Crenolanib Pfizer - C26H29N5O2 443.54 FLT3, 
PDGFRα/β 
0.74, 1, 0.4 - AML, gastrointestinal 
stromal tumor, glioma 
Dacomitinib Pfizer - C24H25ClFN5O2 469.94 EGFR 6 - NSCLC, gastric, head 
and neck/glioma 
Erlotinib OSI Pharmaceuticals Tarceva C22H23N3O4 393.436 EGFR 2 + NSCLC, pancreatic 
cancer 
Gefitinib AstraZeneca Pty Ltd Iressa C22H24ClFN4O3 446.902 EGFR <57 + NSCLC, AML 
Icotinib Zhejiang Beta Pharma Conmana C22H21N3O4 391.15 EGFR 5 + NSCLC 
KW-2449 Kyowa Pharma - C20H20N4O 332.4 FLT3 6.6 - AML 
Lapatinib  GlaxoSmithKline Tykerb C29H26ClFN4O4S 581.058 HER-2, 
EGFR 
9.2, 10.8 + Breast cancer 
Lenvatinib Eisai - C21H19ClN4O4 426.853 VEGFR2/3 <4 + Approved for thyroid 
cancer in Japan 
LY2801653 Eli Lilly and Company - C30H22F2N6O3 552.53 Met, RON <2 - NSCLC 
Neratinib PharmGKB HKI-272 C30H29ClN6O3 557.04 EGFR, 
HER2 
92, 59 - NSCLC, breast cancer 
PD-173074 Pfizer - C28H41N7O3 523.67 FGFR 25 - NSCLC, gastric 
carcinoma, breast 
cancer 
Quizartinib Ambit Biosciences - C29H32N6O4S 560.67 FLT3 <4.2 - AML 
R428 
(BGB-324) 
BerGenBio AS - C30H34N8 506.64 AXL 14 - AML, NSCLC, breast 
cancer 
Tandutinib Millennium 
Pharmaceuticals 
- C31H42N6O4 562.7 FLT3 <100 - RCC, CML 
Tivantinib ArQule ArQule C23H19N3O2 369.42 MET 4 - RCC, breast cancer 
Tivozanib AVEO Pharmaceuticals AV-951 C22H19ClN4O5 454.86 VEGFR1, 
2, 3 
0.21, 0.16, 
0.24 
- RCC, breast cancer 
Vatalanib Bayer Schering and 
Novartis 
- C20H15ClN4 346.813 VEGFR2 37 - NSCLC, DLBCL, 
colorectal 
adenocarcinoma 
* IC50 (half maximal inhibitory concentration) values are the measure of the effectiveness of TKIs in inhibiting the RTKs in 
biochemical assays, Appr: approved. treatm: treatment, HER: human epidermal receptor, EGFR: epidermal growth factor 
receptor, NSCLC: non-small cells lung carcinoma, VEGFR: vascular endothelial growth factor receptor, PDGFR: platelet-
derived growth factor receptor, AML: acute myeloid leukemia, CML: chronic myeloid leukemia, RCC: renal cell carcinoma 
2.8.1 Monoclonal antibodies against ROR1 
The extracellular region of ROR1 contains Ig-like, CRD and KNG domains, which could 
be targeted by monoclonal antibodies. Monoclonal antibodies directed against these 
extracellular domains have been developed as potential therapeutic agents  [245, 247, 286]. The 
anti-ROR1 mAbs may kill cells by direct apoptosis or by activation of complement or 
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immune effector cells. Most effective anti-ROR1 mAbs to induce significant apoptosis in 
CLL cells were those against the CRD and KNG domains [245]. Anti-ROR1 CRD mAb also 
induced apoptosis in pancreatic cancer cell lines. De-phosphorylation of ROR1, the PI3Kδ, 
AKT and mTOR was also observed prior to apoptosis by the treatment of anti-ROR1 CRD 
mAb suggesting inhibition of downstream signaling but there was no effect on ERK and 
PKC proteins. These findings may suggest that ROR1 signaling occurs via 
PI3K/AKT/mTOR axis in pancreatic cancer cell lines. 
The anti-ROR1 mAbs also resulted in killing of melanoma cell lines by direct 
apoptosis as well as complement dependent cytotoxicity (CDC) and antibody dependent 
cellular cytotoxicity (ADCC) [287]. ESTDAB081 and ESTDAB094 melanoma cell lines 
were resistant to direct apoptosis by anti-ROR1 mAbs alone but sensitive to apoptosis by 
anti-ROR mAbs mediated through CDC and ADCC. Knockdown of ROR1 through 
specific siRNA resulted in apoptosis of melanoma cell lines. 
The effects of anti-ROR mAbs in TCL1 transgenic mice expressing ROR1+/CD5+ 
/B220low leukemic B cells as a model for in vivo studies were analyzed [288]. Two anti-
ROR1 antibodies, D10 and 4A5 against different epitopes produced different effects in 
vivo. D10 anti-ROR1 mAb reduced phosphorylation of AKT but 4A5 mAb did not. 
Leukemic cells were cleared from the blood and spleen of transgenic mice following 
intravenous injections of D10 mAb but not by 4A5 [288, 289]. Cirmtuzumab, a humanized 
anti-ROR1 mAb killed tumor cells and was internalized by malignant cells. Cirmtuzumab 
with ADC (antibody drug conjugates) cleared ROR1 expressing CLL cells in xenografted 
mice as well as induced apoptosis of breast and pancreas cell lines in vitro. 
Anti-ROR1 antibodies may also be used to deliver toxins. Immunotoxin (BT-1) from 
Pseudomonas exotoxin (PE38) conjugated with the variable fragments of an anti-ROR1 
mAb showed a dose-dependent and selective binding to leukemic cells from CLL and 
MCL patients, followed by internalization of the immunotoxin and subsequent apoptosis in 
vitro [290]. 
ROR1 expression has been shown to be associated with epithelial-mesenchymal 
transition of tumor cells as indicated above  [267]. Treatment with anti-ROR1 mAbs 
prevented metastasis by down-regulation of proteins involved in cell motility and 
metastasis of breast cancer cell lines  [267]. 
2.8.1.1 Immunotherapeutic strategies targeting ROR1 
ROR1 is highly expressed in many malignancies but not in healthy adult tissues. ROR1 as 
an oncofetal antigen might thus be recognized by the immune system. A humoral immune 
response against ROR1 in CLL patients was observed after vaccination with Ad-CD154 
transduced CLL cells  [235]. Antibodies induced against ROR1 blocked the interaction of 
Wnt5a and ROR1 and reduced proliferation of CLL cells. Lenalidomide, an immune 
modulating drug treatment induced ROR1 antibodies in CLL patients indicating that ROR1 
may be an immunodominant epitope  [291-293]. CLL patients may also mount a type 1 T cell 
response against ROR1 and a humoral response against ROR1  [294, 295]. 
Transgenic leukemic ROR1+ mice immunized with a ROR1 peptide produced high 
titers of anti-ROR1 antibodies which inhibited the engraftment of ROR1+ CLL cells [296].  
ROR1 may thus act as a tumor antigen for vaccination in a similar way as HER2 
derived vaccine in breast cancer patients [297].  
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T cells from healthy donors or CLL patients have also been genetically modified to 
express ROR1-CART targeting ROR1+ tumor cells [248]. CD8+ T cells engineered to 
express specific ROR1-CART lysed CLL and MCL cells but not mature normal cells. 
ROR1-CARTs were shown be as potent as CD19-CARTs in a immunodeficient mice 
model of human MCL [298]. Clinical trials on ROR1-CART are just to be started. 
2.8.2 Tyrosine kinase inhibitors against ROR1 
Most oncogenic RTKs are highly up-regulated and activated in malignant cells but have no 
or low expression and activity in normal tissues [299]. RTKs in tumors might also be targeted 
by TKIs against the intracellular kinase domain  [300]. Axl is an RTK constitutively 
expressed in CLL and by targeting the intracellular kinase domain by a specific inhibitor, 
R428, a robust apoptosis of CLL cells was induced in a dose- and time-dependent manner 
[276]. The VEGFR inhibitors vatalanib and pazopanib decreased phosphorylation of the 
VEGF receptor and induced apoptosis of CLL cells in clinically achievable concentrations 
with a mild cytotoxic effect on healthy B cells [301]. 
Tyrosine kinase inhibitors might also target the intracellular kinase domain of ROR1. 
TKIs against ROR1 have been produced and developed by Kancera (www.kancera.com). 
Our preliminary results indicated that one of the promising ROR1 TKI induced apoptosis 
both in progressive and non-progressive CLL cells but not in normal PBMCs. Our own 
study, which is part of this thesis (Paper V) showed robust cytotoxic activity of this ROR1 
TKI in CLL cells. ROR1 TKI treatment of CLL cells induced dephosphorylation of ROR1 
and subsequent apoptosis. Progressive and non-progressive CLL cells were sensitive to 
ROR1 TKI. ROR1 TKI also showed activity in fludarabine resistant CLL cells. Treatment 
of CLL cells with ROR1 TKI dephosphorylated ROR1. ROR1 TKI induced apoptosis in 
CLL cells via caspase activation, PARP cleavage and downregulation of Mcl-1 and Bcl-2. 
Oral administration of ROR1 TKI in xenografted transplanted NOD SCID mice reduced 
leukemic cells. Our preliminary data also show that ROR1 TKI could induce apoptosis of 
pancreatic, breast and lung cancer cell lines in a dose and time-dependent manner.  
In conclusion, ROR1 may be promising therapeutic target for both ROR1 TKI and 
mAbs in CLL and other malignancies. 
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3 AIMS OF THE STUDY 
 
 Structurally and functionally characterize the receptor tyrosine kinase ROR1 in 
chronic lymphocytic leukemia as a basis for the development of ROR1 directed 
targeted therapy. 
 Develop prototype ROR1 directed unconjugated monoclonal antibodies as a basis 
for development of therapeutic monoclonal antibodies. 
 Develop ROR1 tyrosine kinase inhibitor as a drug candidate. 
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4 RESULTS AND DISCUSSION 
4.1 Paper I 
 Monoclonal antibodies against ROR1 induce apoptosis of CLL cells 
 Leukemia, 26:1348-1355, 2012 
Aim and background of the study: ROR1 is overexpressed in CLL cells both at gene and 
protein levels. The extracellular part of ROR1 consists of an immunoglobulin (Ig) like 
domain, a cysteine-rich domain (CRD) and a kringle domain (KNG) while the intracellular 
part contains a kinase domain, which is constitutively phosphorylated in CLL cells. 
The aim of the study was to produce monoclonal antibodies against different epitopes 
of the external part ROR1 and analyze their apoptotic activity in CLL cells. 
Results: Five anti-ROR1 mAbs were produced; one against Ig-like domain (Ig 3B8 mAb), 
two against CRD domain (CRD IC11 and CRD ID8 mAbs) and two against KNG domain 
(KNG 4A7and KNG 4C10 mAbs). All 5 anti-ROR1 mAbs were tested for staining of 
ROR1 surface expression and showed a strong ROR1 reactivity of CLL cells from 20 
patients. The frequency of ROR1+ cells were as follow; Ig 3B8: 92±1% 
(mean±SEM)(range: 77-98%), CRD 1C11: 94±1% (72-98%), CRD ID8: 88±1% (72-94%), 
KNG 4A7: 93±1 (74-98%), KNG 4C10: 94±1 (84-99%). No ROR1 expression was 
detected on PBMC of healthy donors. The expression of ROR1 was slightly higher in 
progressive compared to non-progressive disease. 
Functional activity of these anti-ROR1 mAbs was assessed for apoptosis measured by 
the annexin V/PI assay. 18h incubation of CLL cells with anti-ROR1 mAbs was chosen as 
optimal. All five anti-ROR1 mAbs induced significant apoptosis in CLL cells as compared 
to controls. Three anti-ROR1 mAbs i.e. CRD 1C11, CRD 1D8 and KNG 4C10 were the 
best to induce apoptosis. Apoptosis induction was confirmed by PARP cleavage. These 
three anti-ROR1 mAbs induced higher apoptosis than the murine or chimeric rituximab 
(anti-CD20) (p<0.0001). Cross-linking of anti-ROR1 antibodies with F(ab´)2 fragments 
significantly enhanced apoptosis. CRD 1D8 and KNG 4A7 induced apoptosis by 
complement dependent cytotoxicity in a similar way as rituximab. KNG 4A7 also induced 
significant killing via antibody-dependent cellular cytotoxicity (ADCC) of CLL cells. 
Discussion: The main goal of the study was to produce a panel of monoclonal antibodies 
against different domains of extracellular part of ROR1 and analyze their cytotoxic 
capacity. 
ROR1 has been shown to be constitutively phosphorylated at the intracellular kinase 
domain and silencing of ROR1 by siRNA induced specific apoptosis of CLL cells [239, 244]. 
ROR1 is not expressed on adult lymphoid and non-lymphoid cells. Thus, ROR1 might be a 
suitable candidate for targeted therapy. A set of mouse mAbs against different ROR1 
epitopes was produced to explore the functional roles of different epitopes. The antibodies 
raised were against different peptide sequences, Ig-like domain(23aa), CRD(15aa) and 
KNG(19aa) derived of extracellular part of ROR1. 
Different staining pattern of the same patient by different ROR1 mAbs may suggest 
structural heterogeneity in the expression of ROR1 and/or difference in the binding affinity 
of mAbs for different epitopes on ROR1. The antibodies against CRD and KNG were 
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highly effective in inducing apoptosis. This finding may be interesting as the CRD and 
KNG regions are assumed to contain binding sites for Wnt-family and non-Wnt ligand 
binding proteins [229, 231, 302, 303]. Apoptosis induction was confirmed by activation of caspase 
8 and caspase 9, covering both intrinsic and extrinsic apoptotic pathways [304]. Apoptosis 
induced by ROR1 mAbs alone was not a result of immune cells as more than 90% of 
PBMCs were CD19/CD5+ B cells and only 3-4% natural killer cells (NK) and monocytes. 
In vitro, 10-50 times more effector cells compared to target cells are needed for a detectable 
ADCC activity  [305]. The IgG1 ROR1 mAbs also induced complement lysis, which may 
suggest a highly conserved CH2 domain of IgG compatible with complement activation 
[306]. It is also known that all CLL cells may not express detectable target molecules 
recognized by a given mAb [307, 308], which is in line with our studies, as we could not detect 
ROR1 on all leukemic cells. This could be due to either low surface expression of ROR1 or 
presence of a subpopulation of ROR1-negative leukemic cells. 
The expression of ROR1 on CLL cells increased when disease progressed from 
indolent to aggressive phase. A high density of RTKs on tumor cells is linked to high 
proliferative potential as well as survival advantage of the tumor cells as an indicator of 
poor clinical prognosis [309, 310]. 
Three of our ROR1 mAbs could induce higher cytotoxicity than murine and chimeric 
anti-CD20 mAbs. Rituximab alone is known to induce a low degree of apoptosis [311], also 
confirmed by our study but cross-linking of rituximab, CDC and ADCC was required to 
enhance the cytotoxicity [312]. The difference in the apoptosis induction by ROR1 mAbs 
could be explained by different binding regions, mAbs of different isotypes and also 
difference in the expression of ROR1 between patients. However, we could not find any 
correlation between ROR1 expression and apoptosis induction by ROR1 mAbs, which has 
been reported for mAbs against CD20 and other RTKs [313, 314]. 
In summary, mAbs were raised against different epitopes of ROR1. These ROR1 
mAbs alone induced apoptosis of CLL cells. 
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4.2 Paper II 
 The tyrosine kinase receptor ror1 is constitutively phosphorylated in chronic 
lymphocytic leukemia (CLL) cells 
 PLoS One, 8: e78339, 2013 
Aim and background of the study: The intracellular part of ROR1 contains a tyrosine 
kinase domain, which is presumed to be involved in intracellular signaling. ROR1 silencing 
by specific siRNA and anti-ROR1 mAbs against extracellular domains induced apoptosis. 
The aim of the study was to analyze different isoforms of ROR1 and their 
phosphorylation pattern. 
Results: A polyclonal anti-ROR1 antibody (pROR1Ab) was produced against the 
intracellular phosphorylated kinase domain of ROR1. The specificity of anti-pROR1 pAb 
was confirmed by treatment with a lambda phosphatase enzyme that resulted in 
disappearance of phosphorylated bands but not the total protein. ROR1 was shown to be 
constitutively phosphorylated at tyrosine and serine residue in all tested CLL patients.  
ROR1 proteins of 105 and 130 kDa were identified in CLL cells by Western blot. The 
105 kDa is considered to be the native and unglycosylated whereas 130 kDa band is 
supposed to be the fully matured and glycosylated protein. The native and immature (non-
glycosylated) 105 kDa ROR1 isoform was found to be more frequently expressed in non-
progressive as compared to progressive CLL patients, which may indicate a correlation 
between glycosylation and disease progression as have been shown for other diseases [315]. 
In addition to 105 and 130 kDa, other bands of 260 kDa and 64 kDa respectively were also 
noted. The 260 kDa band may represent dimerized ROR1 and the 64 kDa a truncated 
ROR1. The expression of different ROR1 isoforms was different among patients. The 
unglycosylated ROR1 105 kDa isoform was observed more frequently in non-progressive 
as compared to progressive patients. 
There was no difference in the phosphorylation intensity for 105 kDa ROR1 isoform 
between progressive and non-progressive CLL patients but was significantly higher for the 
130 kDa ROR1 isoform in progressive as compared to non-progressive CLL patients. 
Phosphorylated 105 and 130 kDa were localized both to nucleus as well as cytoplasm while 
64 kDa was only detected in nucleus. ROR1 was shown to be constitutively phosphorylated 
at serine and tyrosine residues in all tested CLL patients. 
Discussion: Similar to other RTKs, ROR1 could be found of different isoforms, the most 
prominent being the 105 and 130 kDa bands, localized in cytoplasm and nucleus. We could 
also detect a 260 kDa band presumably a dimerized form of the ROR1, similar to ROR2 
which has been shown to be homodimerized [316, 317] as well as heterodimerized [318].  
Posttranslational modification of ROR1 might be of functional significance. ROR1 
was shown to display non-unique glycosylation [273], similar to our study. There are 
potentially seven asparagine residues for N-linked glycosylation and more than 24 serine 
and threonine residues for O-glycosylation that may contribute to different glycosylation 
patterns. The glycosylation pattern may vary from patient to patient and also between cells 
of an individual CLL clone. Tunicamycin and brefeldin induced deglycosylation resulting 
in 100 and 115 kDa bands compared to untreated 130 kDa [273]. Our finding also confirmed 
that non-glycosylated immature ROR1 105 kDa isoform was predominantly expressed in 
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non-progressive patients, suggesting that glycosylation might be associated with disease 
activity as has been shown for other diseases [315]. 
Truncated ROR1 containing 388 amino acids (40 kDa) has been detected in fetal CNS 
tissues and lymphoma and leukemic cell lines [231]. The truncated ROR1 could be due to 
alternative splicing [231] or a cleaved C-terminal fragment (CTF) produced by surface 
proteolytic enzymes [319]. We found that the phosphorylated truncated ROR1 was 64 kDa 
and present in nucleus, suggesting to act as a transcription factor  [268]. The cytoplasmic 
domain of ROR1 may play an important role in cell migration and cytoskeleton remodeling 
by activating genes involved in actin cytoskeleton [320]. Truncated HER2 (P95 HER2) has 
been associated with poor prognosis in breast cancer [321]. 
ROR1 and ErbB2 or HER2/neu are members of type I RTKs that contribute to 
malignant phenotype of several cancers. High expression of HER1/2, VEGFR2 / KRD and 
estrogen receptors and their tyrosine phosphorylation in breast cancer was found to 
correlate to poor prognosis  [322-325]. Fully mature and glycosylated ROR1 may be 
preferentially expressed on the surface, suggesting a relation between ROR1 maturity, 
phosphorylation and disease progression. Mouse ROR1 was shown to be phosphorylated at 
serine position 652, located in the activation segment [326]. NetPhosK software revealed two 
tyrosine residues at 641 and 646 with the probability to be phosphorylated by tyrosine 
kinase. The peptide used for the production of anti-pROR1 was within the activation 
segment of two tyrosine and one serine residues. 
Constitutive phosphorylation of RTKs including ligand-dependent or ligand-
independent plays an important role in cell signaling [327, 328]. Tyrosine phosphorylation 
triggered by other tyrosine kinases is a general mechanism for RTKs. Whether the 
constitutive phosphorylation of ROR1 at tyrosine [329-331] and serine [332, 333] residues is auto 
phosphorylated or not is not clear. ROR1 was shown to have a low degree of auto 
phosphorylation (low catalytic activity), similar to ErbB3 but weaker than ErbB2 [275]. Met 
oncogene which is highly overexpressed in CLL cells [334] has been suggested to 
phosphorylate ROR1 at tyrosine residue by trans-phosphorylation [275]. However, the Met 
oncogene might not be the only one to activate ROR1 as cell lines with low Met level and 
activity could still show ROR1 phosphorylation. No mutational activations have been 
shown for ROR1. 
Binding of antibodies against the CRD and KNG domains induced dephosphorylation 
of ROR1 preceding apoptosis. In case of ligand-independent ROR1 phosphorylation, 
ROR1 mAbs may induce structural conformation that might activate phosphatases causing 
dephosphorylation of ROR1 and subsequently affect downstream signaling pathways [329-
331, 333]. Wnt5a has also been suggested to be ligand for ROR1 [258] and CLL cells have been 
shown to produce Wnt5a [335]. In case of ligand dependent (Wnt5a) activation, the ROR1 
mAbs may disrupt and prevent ligand binding. 
In summary, ROR1 could be detected in different isoforms that were constitutively 
phosphorylated both at tyrosine and serine residues. The intensity of phosphorylation was 
significantly higher in progressive than non-progressive CLL cells. Inhibition of ROR1 
phosphorylation was followed by apoptosis in CLL cells. 
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4.3 Paper III 
 The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells 
induced by ROR1 monoclonal antibodies 
British Journal of Haematology, 169(3):455-458, 2015 
Aim and background of the study: ROR1 is a RTK expressed in many malignancies. It is 
a surface receptor that is involved in cell-cell interactions, proliferation, signaling and 
survival, and has been suggested to be a “survival factor” in CLL [235]. High ROR1 
expression was detected in CLL patients with progressive disease compared to non-
progressive disease [245]. Knockdown of ROR1 by siRNA as well as inhibition of ROR1 by 
monoclonal antibodies (mAb) induced apoptosis in CLL cells [244, 245]. 
The aim of the study was to analyze the cytotoxicity of ROR1 monoclonal antibodies and 
the effect on PI3K/AKT/mTOR signaling pathway. 
Results: We have previously demonstrated that anti-CRD ROR1 mAb induced 
dephosphorylation of ROR1 and subsequently apoptosis of CLL cells [239]. Treatment of 
CLL cells with anti-CRD ROR1 monoclonal antibody in addition to apoptosis induced 
dephosphorylation of ROR1 as well as of the downstream proteins SRC, PI3Kδ, AKT, 
mTOR, CREB. However, an antibody against the Ig-like domain of ROR1 did not induce 
apoptosis. 
Discussion: Anti-CRD ROR1 mAb inhibited the PI3K/AKT/mTOR pathway, which plays 
an important role in the tumorigenesis [336]. This pathway has been used as validated target 
for EGFR and HER-2, suggesting that ROR1 like the EGFR and HER-2 RTKs might be an 
interesting therapeutic target for anti-ROR1 mAbs in malignancies positive for ROR1. 
Recently, another study also has shown that anti-ROR1 D10 mAb which is directed against 
an epitope close to the CRD region induced apoptosis [337] whereas an anti-ROR1 mAb 
against the Ig-like domain did not induce apoptosis [338] similar to the present study. Our 
anti-CRD ROR1 mAb also induced ADDC and CDC, suggesting a multifunctional 
antibody. 
In summary, an anti-CRD ROR1 mAb induced direct apoptosis of CLL cells 
associated with inhibition of PI3K/AKT/mTOR pathway. Further studies are needed to 
explore ROR1 as therapeutic target monoclonal antibodies in the treatment of malignant 
diseases. The selection of epitope of the external part recognized by the monoclonal 
antibody for apoptosis inductions seems to be very important to obtain a therapeutic 
effective monoclonal antibody. 
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4.4 Paper IV 
 Dishevelled proteins are significantly upregulated in chronic lymphocytic 
leukemia 
 Experimental Hematology, accepted, pending revision 2015. 
Aim and background of the study: Dishevelled (DVL) proteins are important proteins of 
Wnt signaling pathways and have been shown to be upregulated in several cancers. Three 
DVL homologs have been identified in human and mouse, which consist of about 750 
amino acids and show high sequence homology. They are expressed during early 
embryogenesis [339] and knockdown mice (DVL2 -/- and DVL3 -/-) die prenatally [340, 341]. 
The aim of this study was to analyze the expression of DVL proteins (DVL1, DVL2, 
and DVL3) in chronic lymphocytic leukemia (CLL). 
Results: DVL1, DVL2 and DVL3 proteins were found to be highly upregulated in both 
progressive and non-progressive CLL patients but low or undetectable in peripheral blood 
of healthy donor. DVL1 and DVL3 were significantly more expressed in progressive than 
non-progressive CLL disease whereas expression of DVL2 was more pronounced in non-
progressive than progressive cases. All three DVL proteins were phosphorylated both at 
tyrosine and serine residues. Inhibition of ROR1 with anti-CRD mAb induced apoptosis of 
CLL cells and dephosphorylated tyrosine and serine residues of DVL2 and DVL3. 
Knockdown of DVL1, DVL2 and DVL3 with siRNA in CLL cells and CLL derived cell 
line (EHEB) was successfully carried out but no apoptosis was detected. 
Important mediators of canonical and non-canonical pathways were also analyzed. 
GSK-3β and β catenin of the Wnt canonical pathway were detected both in progressive and 
non-progressive CLL disease. GSK-3β was found to be statistically more phosphorylated in 
progressive than in non-progressive cases whereas expression of β catenin was more 
pronounced in non-progressive compared to progressive CLL. The difference was 
statistically significant. AKT was found to be phosphorylated in CLL patients, however the 
intensity of phosphorylation was significantly higher in non-progressive cases than in 
progressive CLL cases. PKC and GSK-3α of Wnt non-canonical pathway were also 
detected but there was no significance difference in the intensity of phosphorylation 
between progressive and non-progressive CLL patients. 
Discussion: The aim of the study was to analyze the expression of DVL proteins, their 
phosphorylation status and downstream proteins of Wnt signaling pathways in CLL cells. 
DVL proteins are important mediators of Wnt signaling pathway. Wnt signaling 
pathways are upregulated in several tumors and play a role in cell proliferation and 
migration [342]. Wnt signaling pathways are activated by binding of Wnt ligands to a 
Frizzled receptor inducing in phosphorylation of DVL proteins, which then activate 
downstream signaling pathways involved in cell survival and proliferation [343]. We found 
that DVL1, DVL2 and DVL3 were highly upregulated in both progressive and non-
progressive CLL patients and we could also show phosphorylation both at tyrosine and 
serine residues. Knockdown of DVL proteins were performed to assess their role in 
survival, however, knockdown of DVLs did not induce apoptosis, suggesting they may not 
have a direct role in survival of CLL cells. 
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Activation of Wnt signaling in the presence of the LRP6 co-receptor inhibited 
degradation of β- catenin by GSK-3β [344]. High level of β-catenin and phosphorylated 
GSK-3β were detected in CLL cells, suggesting accumulation of β-catenin in the cytoplasm 
followed by translocation to nucleus where it may activate target genes involved in cell 
cycle progression, differentiation and adhesion. 
ROR1 may also be involved in the activation of non-canonical pathways regulating 
downstream signaling proteins related to cytoskeletal formation and cell adhesion. 
Inhibition of ROR1 by anti-ROR1 antibody induced dephosphorylation of DVL2 and 
DVL3 proteins. Non–canonical proteins such as AKT, PKC and GSK-3α are upregulated 
in CLL cells. Activation of both canonical and non-canonical pathways may not only 
prolong cell survival but could also support cell proliferation and migration [345]. In non-
progressive CLL, high level of DVL2 and activated AKT may inhibit GSK-3β resulting in 
the accumulation of β-catenin and subsequently contributing to cell survival, whereas in 
progressive CLL, high levels of DVL1 and DVL3 may trigger Wnt/PCP pathway resulting 
in cell proliferation and migration. This observation is in agreement with studies by Kaucka 
M et al [346]. 
In summary, all three DVLs were highly upregulated and phosphorylated in CLL 
patients but not detectable in peripheral blood of healthy donors. ROR1 inhibition induced 
dephosphorylation of DVL2 and DVL3. Knockdown of DVL1, DVL2 and DVL3 did not 
induce apoptosis in CLL derived cell line suggesting no direct role in the cell survival. 
More studies are needed to further explore the role of different DVL proteins and the 
mechanism of action in CLL. 
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4.5 Paper V 
 On-target effect of a ROR1 tyrosine kinase small molecule inhibitor by 
apoptosis mediated death in chronic lymphocytic leukemia cells in vitro 
and in vivo 
 Submitted 
Aim and background of the study: Receptor tyrosine kinase-like orphan receptor 1 
(ROR1) is expressed in chronic lymphocytic leukemia (CLL) and other cancers both at 
gene and protein levels. ROR1 belongs to type 1 of receptor tyrosine kinases (RTKs) 
family. ROR1 consists of extracellular, transmembrane and intracellular parts. The 
extracellular part contains an immunoglobulin-like (Ig) domain, the kringle domain (KNG), 
and a cysteine-rich domain (CRD). The intracellular part of ROR1 contains a tyrosine 
kinase (TK) domain that plays an important role in transducing signals downstream. 
Serine/threonine and proline-rich motifs are also present on the intracellular cytoplasmic 
part of ROR1. ROR1 is expressed during embryogenesis and plays a crucial role in 
skeletal, lung and neural organogenesis but is repressed in adult tissues [347]. ROR is 
involved in survival, differentiation, proliferation and polarity as well as tumor like 
behavior such as migration and invasion [348, 349]. 
The main goal of the study was to develop a specific tyrosine kinase inhibitor against 
the intracellular kinase domain and assess the apoptotic effect in CLL cells. 
Results: A biochemical-screening assay was used to select a potential series of small 
molecules from a chemical library and then modifications were made for a better mode of 
action and activity. KAN0439834 was chosen as a promising small molecule tyrosine 
kinase inhibitor drug candidate with specific anti-ROR1 activity. 
Treatment of CLL cells with KAN0439834 (24h) induced equally well apoptosis of 
CLL cells from progressive as well as non-progressive disease. KAN0439834 had the same 
activity on fludarabine resistant CLL cells regardless of 17p- status. The cytotoxic activity 
for peripheral blood mononuclear cells (PBMC) from healthy donors was 60-fold less. 
Apoptosis was measured by annexin V/PI as well as the MTT assay and confirmed by 
PARP cleavage, caspase-3 and downregulation of the anti-apoptotic proteins Bcl-xL and 
Mcl-1. KAN0439834 treatment of CLL cells dephosphorylated ROR1 in a dose-dependent 
manner as early as after 15 minutes. ROR1 downstream signaling proteins including SRC, 
PI3K, AKT and CREB seemed to have also reduced their degree of phosphorylation 
intensity upon treatment with KAN0439834 after 2h. 
Cytotoxicity and specificity of KAN0439834 were compared to other kinase inhibitors, 
which are in clinical trials. KAN0439834 was found to be more potent and highly specific 
compared to other kinase inhibitors in vitro as idelalisib, ibrutinib, dasatinib, sunitinib, 
gefitinib and others. 
NOD-SCID mice were xenografted with human leukemic CLL cells. Oral treatment 
with KAN0439834 significantly reduced the number of leukemic cells and the degree of 
ROR1 phosphorylation. Toxicity was minimal. 
Discussion: Biochemical assay was used to screen a large library of 80,000 small 
molecules for anti-ROR1 activity. High-throughput screening (HTS) generated a set of 222 
primary hits tested in dose-response experiments. The hits were subjected to a single point 
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redox assay for identification of redox active compounds. 77 hits showed redox activity and 
were removed. Data on identity, purity, chemical stability and solubility was collected. 6 
chemical clusters and 4 singletons were identified as promising. A chemistry-based 
program on one promising hit (KAN0173631) was initiated. 900 analogs have been 
synthesized, resulting in the present lead series. KAN0439834 is one of the promising 
candidates in the lead series with a molecular weight of 530 kDa. KAN0439834 contains 
no apparent toxicophores and is metabolically stable in human hepatocytes. 
ROR1 has been shown to be highly expressed at gene and protein levels in CLL cells 
as well as other malignancies [235, 247, 252, 255]. Therapeutic approaches are underway to target 
ROR1 in different malignancies. In paper I, we showed that the CRD and KNG domains of 
the extracellular part of ROR1 could be targeted by monoclonal antibodies inducing 
apoptosis in CLL cells. We have also shown that ROR1 is constitutively phosphorylated in 
the TK domain of CLL cells [239]. Our own developed drug KAN0439834 against the 
intracellular kinase domain of ROR1 was tested in CLL cells. KAN0439834 induced 
specific apoptosis of CLL cells in a time and dose dependent manner. Since KAN0439834 
is against the kinase domain, phosphorylation status of ROR1 was assessed after treatment 
with the drug. KAN0439834 reduced phosphorylation of ROR1 within 15 minutes of 
treatment with CLL cells. KAN0439834 also triggered higher cytotoxicity of leukemic B 
cells but not of normal T cells from the same CLL patients. Specificity index for 
KAN0439834 was in the range of 60, i.e. killing CLL cells 60 times more than healthy 
PBMCs. Apoptosis was confirmed by PARP cleavage and downregulation of anti-
apoptotic proteins as Mcl-1 and Bcl-xL. Treatment of CLL cells with KAN0439834 
reduced the phosphorylation of SRC, PI3K, AKT and CREB but longer exposure time was 
needed as compared to dephosphorylation of ROR1. 
KAN0439834 was found to be equally effective against fludarabine resistant CLL cells 
with or without 17p- as indolent CLL cells. Other kinase inhibitors currently in preclinical 
and clinical studies were compared with KAN0439834. The specificity index for 
KAN0439834 was about 60 (median value) as compared to < 5 for other kinase inhibitors. 
Ibrutinib (PCI-32765), which has been approved for CLL and MCL, showed lesser 
cytotoxic activity and specificity than KAN0439834 in our in vitro assays. 
In summary, KAN0439834 was developed as a completely new drug and showed high 
potency and specificity for CLL cells. KAN0439834 was equally effective in leukemic 
cells from all CLL groups irrespective of disease stage. KAN0439834 dephosphorylated 
ROR1. In a mouse model KAN0439834 confirmed the antitumor effect. More studies are 
warranted to fully understand the therapeutic value of ROR1 TKI. However, this is the first 
candidate of a novel class of anti-cancer drugs. 
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5 CONCLUSIONS 
ROR1 is a receptor tyrosine kinase like orphan receptor 1, located on chromosome 1 
(1p31.3), 2814bp and 937 amino acids sequence in human. Initially ROR1 was thought to 
be exclusively expressed in CLL but now we know that ROR1 is expressed in other cancers 
including hematological malignancies as well as solid tumors. 
ROR1 exists in different isoforms due to posttranslational modifications. The native 
immature and unglycosylated ROR1 is present as a 105 kDa protein and the fully mature, 
glycosylated ROR1 as a 130 kDa. We also showed a 64 kDa truncated ROR1 localized to 
the nucleus. The truncated 64 kDa ROR1 might act as transcription factor, although the 
target genes are not yet identified. A band of 260 kDa was also detected presumably 
representing a dimerized form of ROR1. All isoforms of ROR1 were shown to be 
constitutively phosphorylated at tyrosine and serine residues. Phosphorylation of ROR1 
might be important in transducing downstream signaling which may contribute to cell 
survival. 
Monoclonal antibodies (mAbs) were produced against different extracellular domains 
of ROR1. The expression of ROR1 was higher in progressive as compared to non-
progressive disease. All mAbs showed cytotoxicity against CLL cells in a dose and time 
dependent manner. mAbs against the CRD and KNG domains were the most effective in 
inducing apoptosis of CLL cells. CRD and KNG domains contain binding modules for Wnt 
and non-Wnt ligand family proteins. Cross-linking of ROR1 mAbs with (Fab') fragments 
enhanced apoptosis of CLL cells. The mAbs were also active in ADCC and CDC. CRD 
and KNG ROR1 mAbs showed higher cytotoxicity than rituximab. 
An anti-phospho ROR1 polyclonal antibody (pROR1 pAb) was produced against the 
intracellular kinase domain of ROR1. ROR1 was found to be constitutively phosphorylated 
in CLL. The anti-pROR1 pAb could detect phosphorylation of different isoforms. 
Phosphorylation intensity of the 130 kDa ROR1 isoform was higher in progressive than in 
non-progressive CLL. Treatment with anti-ROR1 CRD and KNG mAbs dephosphorylated 
ROR1 and subsequently induced apoptosis. ROR1 dephosphorylation was accompanied by 
downregulation of downstream proteins as SRC, PI3K, AKT, mTOR and CREB. 
DVL proteins are important proteins of Wnt signaling pathways and have been shown 
to be highly expressed in various cancers. DVL1, DVL2 and DVL3 were highly 
upregulated in CLL cells. The expression of DVL1 and DVL3 was found to be higher in 
progressive than in non-progressive CLL cells while DVL2 was more pronounced in non-
progressive than in progressive CLL. DVL proteins were phosphorylated both at tyrosine 
and serine residues. ROR1 inhibition with anti-ROR1 mAb induced dephosphorylation of 
DVL2 and DVL3. Knockdown of DVL proteins in the CLL cells and EHEB cell line did 
not induce apoptosis, suggesting that DVL proteins may not have a direct role in the 
survival of CLL cells. 
A biochemical assay was performed to screen a library of small molecules for anti-
ROR1 activity and a synthesizing program was initiated. A completely novel molecule 
(KAN0439834) was produced with a molecular weight of 530 kDa. KAN0439834 induced 
apoptosis of CLL cells in a dose dependent manner and dephosphorylated ROR1 within 15 
minutes at a dose of 50 nM. Apoptosis was confirmed by PARP cleavage and 
downregulation of anti-apoptotic proteins as Mcl-1 and Bcl-xL. KAN0439834 was equally 
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effective in CLL cells derived from patients irrespective of disease stage. KAN0439834 
was found to be more active than other tyrosine kinase inhibitors in vitro, which are 
approved, including ibrutinib and idelalisib. KAN0439834 showed a high specificity 
against CLL cells. KAN0439834 significantly reduced the number of CD45+CD19+ 
ROR1+ cells in non-SCID mice xenografted with human CLL cells. KAN0439834 has also 
showed high cytotoxic capability against pancreatic, breast and lung cancer cell lines (data 
not published). 
In summary, ROR1 is expressed in CLL cells as well as in other malignancies. Anti-
ROR1 mAbs against KNG and CRD domains as well as a small molecule TKI, 
KAN0439834 induced specific apoptosis of CLL cells. KAN0439834 is the first drug 
candidate of a novel class of anti-cancer drugs. 
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6 FUTURE PERSPECTIVES 
CLL is the most common leukemia in the Western world. During the last decade, an 
enormous progress has been seen in the understanding of the molecular and cellular 
biology of the disease as well as in the treatment of the patients. These achievements have 
provided opportunities to design and develop innovative therapeutic strategies for CLL. 
Despite these developments, CLL still remains an incurable disease although an 
improvement in survival is noted. The availability of new active agents has improved the 
outcome for CLL patients but elimination of the malignant cells and normalization of the 
immune system has not yet been reached. Still most patients with active CLL die from the 
disease or its complications. 
ROR1 has during the last decade shown up to be an interesting structure for targeted 
therapy. There are several reasons for that, the unique expression in malignant cells 
compared to normal tissues, the importance of ROR1 for several functions of malignant 
cell survival, proliferation, metabolism and metastasizing capacity. However, it is urgently 
needed to have a better understanding on the biology of ROR1 to be able to optimize 
therapeutic approaches, in spite of that promising drug candidates have been produced. 
Many RTKs have been implicated of significant importance in various human 
malignancies [220, 350]. The ROR1 RTK has been shown to be highly expressed in many 
cancers but not in normal tissues. The role of ROR1 in cancer is not fully known and needs 
to be further explored. 
Targeting of ROR1 with small molecules and mAbs induced apoptosis of CLL cells in 
vitro and in vivo. Humanized antibody (cirmtuzumab) against ROR1 has already entered 
clinical trials in CLL (https://clinicaltrials.gov/ct2/show/NCT02222688). However, it is 
important to select an optimal epitope for the external part of ROR1 to utilize maximum 
apoptotic effect. In this regard cirmtuzumab may not be the best and ongoing clinical trial 
has been halted due to insufficient clinical effect. Several other malignancies may also be 
candidates for ROR1 mAb therapy as ALL, breast cancer, lung cancer, pancreatic cancer, 
ovarian cancer and non-Hodgkin’s lymphoma of the B cell type. Clinical trial selecting 
mAbs against the CRD and KNG region might be of preference. In this regard, it is also of 
interest to note that ROR1-CART is in clinical development for CLL and pancreatic 
carcinoma. 
ROR1 TKI has shown promising results in a mouse CLL model and pancreatic 
carcinoma animal studies are in progress. Step by step pharmacological characteristics of 
ROR1 TKI will be optimized with improved efficacy. The first clinical trials are expected 
to be initiated within 1-2 years. In addition to CLL ROR1 TKI might also be tested in 
breast cancer, lung cancer, pancreatic cancer, ovarian carcinoma and different ROR1 
expressing hematological malignancies. 
ROR1 as a uniquely expressed antigen of tumor cells might also be of interest to be a 
target for active specific immunotherapy. ROR1 seems to be spontaneously recognized by 
the patient’s immune system. Pre-clinical animal studies are in progress. A ROR1 
therapeutic cancer vaccine might be optimally used when cytoreduction has been achieved 
with ROR1 TKI and/or mAb to maintain disease control. 
To be able to optimize ROR1 therapy, biomarker tests should be developed 
(companion diagnostics). Such an approach should facilitate selection of patients and the 
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therapeutic evaluation of early clinical trials. Our pROR1 antibody in combination with 
ROR1 antibodies might be a valuable tool. 
Targeting ROR1 is a new principle with other mechanisms of action than existing anti-
cancer drugs. ROR1 directed drugs represent a novel class of anti-cancer drugs and might 
add to the therapeutic arsenal and as such improve the prognosis for several types of 
malignancies, hematological diseases as well as solid tumors. 
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